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Two decades after the World Health Organisation (WHO) declaration of tuberculosis (TB) as 
a global emergency, the disease remains a public health crisis of epic proportions. The 
emergence of drug resistant strains of Mycobacterium tuberculosis, the etiologic agent of TB, 
and the convergent human immunodeficiency virus (HIV) epidemic places a devastating 
burden on an already weakened public health care system in South Africa. Rapid and 
accurate detection of drug resistance to first and second line drugs to guide effective 
treatment of TB is central to control of the disease and in preventing further dissemination of 
drug resistant strains. Knowledge of the underlying resistance mechanisms driving drug 
resistance in M.tuberculosis is pivotal in the design of rapid molecular based assays and will 
impact of the development of novel drugs and regimens for the disease. 
The manuscript in chapter 2 of this thesis, entitled Dynamics of antimicrobial resistance in 
Multi-Drug and Extensively Drug resistant strains of Mycobacterium tuberculosis in 
KwaZulu-Natal, South Africa, demonstrated the diversity of the resistance mechanisms 
amongst the multidrug resistant (MDR) TB strains currently circulating in the KwaZulu-
Natal province of South Africa by the analysis of the rpoB, katG, inhA, pncA and embB genes 
associated with resistance to key drugs used in the treatment of TB. Multiple drug resistance 
mechanisms in the MDR-TB isolates suggests that the strains emerged separately and 
acquired resistance mutations independently. The findings of this study also confirms the 
clonality of the XDR-TB epidemic demonstrated by the predominance of the 
F15/LAM4/KZN strain family and reveals that MDR-TB strains are evolving and spreading 
via transmission. 
 
The manuscript in chapter 3 of this thesis, entitled Streptomycin resistance in the 
F15/LAM4/KZN strain of Mycobacterium tuberculosis is mediated by lineage-specific 
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alteration of the gidB gene, demonstrated that streptomycin (STR) resistance in the 
F15/LAM 4/KZN MDR and XDR-TB strains was mediated by a rare, 130bp deletion within 
the gidB gene of M.tuberculosis leading to a complete disruption of the gene. Classical 
mutations in the rpsL gene mediated STR resistance in the remaining strain families. 
Widespread STR resistance has resulted in the exclusion of the drug from current treatment 
regimens. The findings of this study support the decision of policymakers and cautions the 
application of the drug in the absence of drug susceptibility testing. 
The manuscript in chapter 4 of this thesis, entitled Moxifloxacin resistance in the 
F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis, 
demonstrated that the F15/LAM4/KZN XDR strain harboured the A90V gyrA mutation 
associated with high level ciprofloxacin (CPX) and ofloxacin (OFX) resistance and correlated 
with increased minimum inhibitory concentrations (MIC) for moxifloxacin (MXF). The 
results of this study cautions the utilization of MXF as part of empiric treatment protocols in 
the absence of moxifloxacin MIC data of the circulating XDR strains in an area. It also raises 
concerns regarding the regarding the use of moxifloxacin in KwaZulu-Natal. Furthermore, 
the current breakpoint defining resistance to MXF is of concern and requires revision. 
The manuscript in chapter 5 of this thesis, entitled Evaluation of Capreomycin in the 
treatment of the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium 
tuberculosis demonstrated that the A1401G rrs mutation was the main mechanism mediating 
resistance to the aminoglycosides, kanamycin (KAN) and amikacin (AMIK); and to 
capreomycin (CAP). CAP was reintroduced into TB treatment protocols without prior drug 
susceptibility testing. This results of this study demonstrates high level resistance to CAP and 
urges careful consideration in the application of CAP the KwaZulu-Natal province. 
Furthermore, concerns regarding the high breakpoint value that defines CAP resistance as 
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compared to wild-type MICs for the drug results in misdiagnosis of resistance that results 
inadequate patient treatment and amplifies resistance. 
The manuscript in chapter 6 of this thesis, entitled KZN Multidrug and Extensively drug 
resistant strains of Mycobacterium tuberculosis remain susceptible to Linezolid and 
para-Amino salicylic Acid, demonstrated that the mechanisms most commonly associated 
with resistance to the linezolid (LIN) and para-amino salicylic acid (PAS) were absent in the 
MDR and XDR-TB strains in this study. Mutations detected in the drug targets were lineage 
specific markers rather than resistance mechanisms. This study also highlights the poor 
understanding of resistance to these drugs and the need for further study to allow for 
resistance detection to be incorporated into diagnostic assays, thus prolonging the utility of 
these drugs.  
 The manuscript in chapter 7 of this thesis, entitled Efflux mediated drug resistance in 
clinical isolates of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa, 
demonstrated the role of efflux pumps in mediating low level resistance. The results of this 
study supports the hypothesis that efflux activity leads to decreased intracellular antibiotic 
concentrations, thereby allowing the survival of a sub-population of bacteria under the sub-
inhibitory level of the antibiotic, from which resistant mutants emerge, leading to clinically 
significant levels of resistance. The results of this study strongly supports the application of 
efflux pump inhibitors as adjunctive to the current treatment protocols. 
The results emanating from this thesis has contributed to the body of knowledge of drug 
resistance in M.tuberculosis, especially in the KwaZulu-Natal province of South Africa. 
Furthermore, the results can be used to guide treatment protocols and contributes to the future 







1.1 Background  
Tuberculosis has plagued mankind since antiquity. The discovery of Mycobacterium 
tuberculosis, the etiologic agent of TB, by German bacteriologist, Robert Koch was the 
cornerstone in history of the disease, which subsequently led to the development of modern 
chemotherapy.(1–3) However, soon after the discovery of STR, the first described antibiotic 
effective against M.tuberculosis, reports of resistance emerged. This was mainly due to the 
use of the drug as monotherapy. The realization that M.tuberculosis rapidly develops 
resistance when treated with only one drug, paved the path for modern combination 
regimens.(4) 
M.tuberculosis has evolved over decades, and despite advances in the development of anti-
TB drugs, the organism is now capable of causing severe untreatable forms of the disease. 
Multi-drug resistant (MDR-TB) strains of M.tuberculosis are resistant to isoniazid (INH) and 
rifampicin (RIF), the most effective drugs in the current multidrug regimen. MDR-TB strains 
that display additional resistance to the fluoroquinolones or the injectable second line drugs 
are classified as extensively drug resistant (XDR-TB).(5) More recently, resistance beyond 
XDR-TB has been described as to totally drug resistant (TDR-TB). These isolates display 
resistance to all available first and second line drugs available.(6) 
Major advances in molecular based techniques and the whole genome sequence of 
M.tuberculosis has provided a wealth of information on the mechanisms mediating resistance 
to the key anti-TB drugs, leading to the development of rapid diagnostic assays with the 
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ability to detect M.tuberculosis infection and resistance to rifampicin (RIF) concurrently. 
(7,8) However, detection of resistance to second line drugs still depends heavily on 
mycobacterial culture methods in liquid or solid media. These techniques are most accurate in 
determining resistance to INH and RIF. Susceptibility testing for second line drugs is more 
complicated and less reliable. Furthermore, results from these methods are only available 
weeks to months later.(9) During this period, inadequate treatment allows for the 
development of further resistance and a population of individuals transmitting drug resistant 
strains of TB.(5) 
Modern molecular diagnostics are not dependent on culture techniques that require the slow 
growth of M.tuberculosis. Instead, these methods depend on the association of genetic 
mutations in resistance conferring genes of the pathogen. The accuracy of these tests depend 
on the relationship of the mutation and phenotypic drug resistance in the isolate bearing the 
mutation.(9) This relationship is well established for RIF and INH, but remains vague in the 
case of subsequent drugs.(7,8) The mutations have also been reported to vary geographically 
and the diversity of mechanisms mediating resistance and drug targets has posed a further 
challenge. (10) 
Prolonged treatment for drug resistant TB supports the adaptation and survival mechanisms 
in M.tuberculosis. Increased bacterial fitness resulting in accelerated transmission and the 
induction of efflux mechanisms has been described. Efflux pumps play a role in the extrusion 
of toxic substances and metabolites from the bacterial cell. However, prolonged antibiotic 
exposure has allowed M.tuberculosis to adapt efflux mechanisms to extrude vital drugs and 
escape the effects of the most potent drugs available for eradication of the disease.(11) 
1.2 Epidemiology of Tuberculosis 
3 
 
According to the 2014 global TB report by the WHO, it has been estimated that 9.0 million 
(range, 8.6 million- 9.4 million) incident cases of TB were reported globally in 2013 and 
approximately 1.5 million deaths resulted from the disease. Of these, 0.4 million deaths 
occurred in HIV positive people and 210 000 deaths were attributed to MDR-TB. 3.5% of the 
incident cases and 20.5% of previously treated cases were estimated to be MDR-TB. (12) 
WHO identified 22 high burden countries since 2000, accountable for 82% of all TB cases 
worldwide. The 6 countries recording the highest burden of disease include, India (2.0 
million- 2.3 million), China (0.9 million- 1.1 million), Nigeria (340 000- 880 000), Pakistan 
(370 000- 650 000), Indonesia (410 000- 520 000) and South Africa (410 000- 520 000). (12) 
South Africa, together with Indonesia, ranks 5th amongst the 22 high TB burden countries: 
1.8% of the incident cases and 6.7% of previously treated cases are MDR-TB. The estimated 
epidemiological burden of TB in SA, includes a prevalence of 715 cases per 100 000 
population and incidence of 860 per 100 000 population. (12) 
1.3 Diagnosis of Tuberculosis & Drug Susceptibility Testing 
Early diagnosis and drug susceptibility testing is central to the management of TB. Diagnosis 
of TB is still reliant on sputum smear microscopy and culture based technology.(13) 
Differential staining of mycobacteria is based on the acid fast staining of the organism, 
resulting from the mycolic acid structure of the bacterial cell wall. Sputum smear microscopy 
using the Ziehl-Neelsen (ZN) staining technique is applied to the detection of M.tuberculosis. 
The specimen is stained with phenol fuschin, followed by decolourisation with acid alcohol. 
Methylene blue or malachite green is applied as a counterstain. Auramine-rhodamine staining 
is an alternate to the ZN stain. This technique employs potassium permanganate as a 
counterstain following decolourisation with acid alcohol. The fluorescence of the bacteria is 
visible under UV illumination. (14) 
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Cultivation of M.tuberculosis is a sensitive and specific method for the diagnosis of TB. The 
basic types of culture media include; Lowenstein-Jensen (LJ), an egg-based medium; 
Middlebrook 7H10/11, agar-based media and liquid media such as Middlebrook 7H9. (15) 
Conventional culture based methods requires 3-6 weeks for growth and isolation. (16) 
Culture of M.tuberculosis in liquid media is the current reference method for the diagnosis of 
M.tuberculosis. This method requires adequate digestion and decontamination of samples 
prior to cultivation in media. Liquid media is associated with higher recovery of tubercle 
bacilli  and shorter time to detection.(5) Colorimetric systems such as the BACTEC (Johnson 
Laboratories) and BACTEC-MGIT (Johnson Laboratories) are culture based assays that have 
improved the time to detection of M.tuberculosis.(16)  
The recent Xpert MDR/RIF (Cepheid) assay is a polymerase chain reaction (PCR) based 
assay that utilizes molecular beacon technology. The test has a significantly higher sensitivity 
that sputum smear microscopy. The test is a fully automated, rapid diagnostic assay that 
simultaneously diagnoses TB and detects RIF resistance. This test allows for the rapid 
initiation of treatment for drug resistant TB pending confirmation of drug susceptibility 
testing. (17) 
Drug susceptibility testing on solid media remains the gold standard for phenotypic 
determination of drug resistance. This is mainly due to its standardisation on solid media and 
reproducibility. This technique involves incorporating the drug into the media, thereafter 
inoculating the sputum specimen directly onto the medium or indirectly by inoculating the 
media with culture isolated from the sputum specimen. The 1% proportion method is the 
most common technique used to determine susceptibility. Microplate assays have been tested 




1.4 Molecular Typing of M.tuberculosis 
1.4.1 Typing Methods 
M.tuberculosis was initially believed to be a highly homogenous organism and variations in 
disease presentation were mediated by the host immune response. Modern molecular 
techniques have increased our capacity to distinguish between strains of M.tuberculosis. 
Restriction fragment length polymorphism (RFLP) typing is the most common technique 
adopted to differentiate between M.tuberculosis strains. The IS6110 specific insertion 
sequence displays characteristic binding patterns that can be used to compare isolates. (22) 
PCR based typing methods such as mycobacterial interspersed repetitive units-variable 
number of tandem repeats (MIRU-VNTR), spacer oligonucleotide typing (spoliogotyping), 
strain specific PCR amplification have also been applied to distinguish between strain types. 
More recently, whole genome sequencing technology allows for a greater degree of 
discrimination of M.tuberculosis isolates.(23) 
1.4.2 Circulating Strains 
To date, seven major strain families have been described globally and are further divided into 
subfamilies. These include the East African-Indian (EAI), Haarlem (H), Central and Middle 
Eastern Asia (CAS), European Family X, Default Family T, W-Beijing and Latino-American 
and Mediterranean (LAM). In South Africa, strain families have been reported to vary 
geographically. The TB epidemic in the Western Cape province of South Africa is 
characterised by 4 strain types, the Beijing, F11, F28 and DRF 150. The Beijing strain family 
is the most prevalent strain family, endemic to China and neighbouring countries of 
Mongolia, South Korea and Thailand. This strain type is identified by spoligotype signature 
that lacks spacers 1 to 34 and the IS6110 RFLP signature is the inverted IS6110copy within 
the DR region. The F11 strain family is characterised by the lack of spoliogotype spacers 9 to 
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11, 21 to 24 and 33 to 36 and the presence of 11 to 19 IS6110 RFLP bands that serves as 
unique markers for identification of this family. The F28 family found in South Africa is 
identical to S strain family endemic to Sicily and Sardina. The DRF 150 genotype was 
identified in an outbreak of an emerging resistant non-Beijing strain. This genotype is 
characterised by 5 IS 6110 insertions and high level resistance to INH, RIF and STR. In 
KwaZulu-Natal, the F15/LAM4/KZN, Beijing, F28 and F11 families have been described. 
The F15/LAM4/KZN and Beijing are the predominant strains driving the drug resistant 
epidemic in the province. (24) The F15/LAM4/KZN strain has evolved from 1995 from a 
single phenotype to XDR-TB. (25) This strain family was also attributed as the strain 
responsible for the 2006 outbreak of XDR-TB in the province.(26) The F15 family belong to 
the major Latino-American and Mediterranean family and correspond to the LAM4 sub-
family. The spoligotype pattern lacks spacers 21-24, 33-36 and 40 and has a unique RFLP 
pattern. Spoligotyping of XDR-TB strains from 7 provinces in South Africa revealed high 
genotypic diversity, which included 7 internationally recognised strain families (Beijing, 
LAM, EAI, the T, H, S and X3 families). The Beijing strain family represented majority of 
the isolates. 
1.5 Treatment of Tuberculosis 
1.5.1 Historical overview of tuberculosis treatmentThe era of antibiotic treatment of TB 
began in 1946, with the discovery of STR, the first antibiotic effective against 
M.tuberculosis. However, its ability to consistently cure TB was questioned when patients 
were relapsing after 3 months of STR monotherapy. This was confirmed by the discovery 
that M.tuberculosis rapidly develops resistance when treated with only one drug. (27–30)The 
next decade saw the development of multiple drugs with alternate mechanisms of action 
against M.tuberculosis, including INH, PAS, KAN and cycloserine. This gave rise to 
combination therapy of 18 months duration. The introduction of RIF in 1963, was a major 
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breakthrough in treatment, as it reduced treatment duration to 9 months. Empiric observation 
and the subsequent development of drugs with activity against M.tuberculosis over the next 4 
decades gave rise to the current 4 drug regimen. The use of combination therapy reduced the 
occurrence of resistance and became a standard of care for TB therapy.(4,31) A further 
rationale for combination therapy is based on the premise that 3 population subtypes 
characterize cavitary TB disease; bacilli in the log phase of growth and slow replicating 
bacteria in hypoxic and acidic conditions. Multidrug regimens combining INH, RIF and PZA 
actively inhibits each of the population subtypes.(31,32) 
1.5.2 Current Treatment  
Drug Susceptible Treatment 
Current treatment guidelines recommend a two-phase treatment plan for 6 months for drug 
susceptible (DS) TB. The first phase of 2 months includes a combination of INH, RIF, 
ethambutol (EMB) and pyrazinamide (PZA), known as the intensive phase. The second phase 
of 4 months is treatment with INH and RIF, known as the continuation phase. This regimen is 
currently applied to the treatment of pulmonary TB and most forms of extra pulmonary TB. 
Guidelines further differentiate between new cases (treatment naïve) and previously treated 
cases (previously treated for at least 1 month). Patients previously treated with anti-TB drugs 
are managed with caution due to the risk of inducing drug resistance.(33,34) Figure 1.1 
depicts the clinical management algorithm for TB treatment.(34) 
Drug Resistant Treatment 
Multidrug Resistant TB 
Tuberculosis programmes adopt a combination of standardised and individual based 
treatment regimens for the management of drug resistant TB. The application of standardised 
regimens for MDR-TB cases is confirmed using drug susceptibility testing for the patient or 
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generalised data representing a particular patient population. Individualised regimens utilize 
patient specific data, including prior anti-TB drug use and drug susceptibility testing to tailor 
a drug regimen. In the absence of, or limited drug susceptibility testing data, empirical 
regimens are applied.(5) Table 1.1 summarises the stepwise selection of drugs applied to the 
management of drug resistant TB.(34) 
The recommended regimen for MDR-TB should comprise of at least 4 active second line 
drugs (Table 1.2 shows WHO grouping of anti-TB drugs), a fluoroquinolone (moxifloxacin 
(MXF), gatifloxacin or levofloxacin); an injectable aminoglycoside (CAP, AMIK, KAN); a 
first line drug to which the isolate is susceptible and one group 4 drug (cycloserine, PAS, 
terizidone, protionamide, or ethionamide). Drugs from group 5 are used if 4 active drugs are 
not available from the former groups. The intensive phase of treatment, using the injectable 
aminoglycosides is a minimum of 8 months, followed by a continuation phase of treatment of 
12-18 months. WHO recommends that treatment should be guided in accordance to culture 
conversion and should generally continue for 18 months after the first negative sputum 
smear. (5) 
Extensively Drug Resistant TB 
XDR-TB is associated with poor treatment outcomes and significantly higher mortality when 
compared to MDR-TB, especially in people co-infected with HIV. Clinical data on the 
management of XDR-TB remains limited. (5) Whilst no defined regimen has been shown to 
be successful in the treatment of XDR-TB, reports suggest the use of at least 6 drugs in the 
intensive phase of treatment and 4 drugs in the continuation phase of treatment. (5) 
The selection of these drugs, based on WHO recommendations includes the use of PZA or a 
first line drug that is effective against the infecting strain; a group 2 injectable 
aminoglycoside antibiotic, if the strain is susceptible to these drugs; a group 3 new generation 
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fluoroquinolone such as MXF or gatifloxacin. All the drugs belonging to group 4 may be 
used, only if these have not been used extensively in a previous treatment regime. Two or 
more drugs from group 5 may be used, bedaquiline and delamanid are recommended. Drugs 
that are approved for compassionate therapy may also be applied to the management of XDR-
TB. High dose INH is only recommended for treatment in strains with low-level INH 





Figure 1.1: Treatment regimens and monitoring in new, previously treated, and MDR tuberculosis cases- Reproduced with permission from 




Table 1.1: WHO-recommended stepwise approach to design a regimen for multidrug-




*An anti-tuberculosis drug is thought likely to be effective when the drug has not been used in 
a regimen that failed to cure the patient; drug-susceptibility testing done on the patient's M. 
tuberculosis strain shows that it is susceptible to the drug (drug-susceptibility testing for 
isoniazid, rifampicin, and group 2 and 3 drugs is deemed reliable; drug-susceptibility testing 
for all other drugs is judged not reliable enough for individual patient management); no 
known resistance to drugs with high cross-resistance; no known close contacts with 
resistance to the drug; and drug resistance surveys show that resistance is rare to the drug in 
patients with similar tuberculosis history. This final criterion is relevant in the absence of 
drug-susceptibility testing or for drugs in which individual drug-susceptibility testing is not 
reliable. Information from all five criteria is not always possible to be ascertained. Therefore, 




Table 1.2: Classification of drugs used to treat drug susceptible and drug resistant 
tuberculosis. According to the grouping of the World Health Organisation(5) 
Group Drugs 












Group 3: Second Line – Oral 










Para-amino salicylic acid 
Group 5: Third Line  











High dose of isoniazid 
 
1.5.3 Future Treatment  
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New treatment regimens for the treatment of TB include repurposing of older TB drugs in 
new combinations as well as the introduction of new drugs.. Repurposed drugs include the 
use of LIN, meropenem/clavulanic acid and co-trimoxazole. Meropenenem/clavulanic acid 
has shown promising activity against M.tuberculosis, in combination with LIN. Co-
trimoxazole has also been indicated for treating MDR-TB.(4,34) 
High-dose rifapentine is currently under investigation to replace RIF and potentially reduce 
the current treatment duration. Rifapentine demonstrates similar activity to RIF but has a 
longer half-life that allows for better exposure. Furthermore, studies have revealed that the 
optimal dosage for RIF has never been established, thus leading to trials applying higher 
dosages of RIF. However, a major shortfall of rifamycin antibiotics is its interaction with 
antiretroviral therapy in HIV co-infected patients.(4,34) 
Bedaquiline, a new antibiotic, is a diarylquinoline antibiotic with proven efficacy against 
drug susceptible and resistant strains of M.tuberculosis. After completion of phase IIb clinical 
trials the drug received conditional approval for the treatment of MDR TB. The drug is 
currently applied on the basis of compassionate therapy. This drug has been associated with 
toxicities and has not yet been applied to a phase III trial, due to the cardiotoxicity associated 
with the drug. The use of this drug is limited to patients with documented resistance to 
several other drugs.  Reports of resistance to the drug have already emerged despite its recent 
introduction. (4,34) 
Delamanid, a nitro-dihydro-imidazooxazole is also a new drug introduced to TB treatment. 
The drug is currently under evaluation in phase III clinical trials for the treatment of MDR 
TB. This drug has demonstrated efficacy against drug susceptible and resistant strains of 




1.6 Mechanisms of Drug resistance in Mycobacterium tuberculosis 
1.6.1 Genetic Resistance Mechanisms 
Antibiotic resistance in M.tuberculosis occurs by the acquisition of mutations in genes that 
code for drug targets or those involved in drug activation, allowing for the selection of 
resistant strains mediated by sub-optimal therapy. Unlike other bacteria, resistance is not 
acquired via horizontal gene transfer by mobile genetic elements. Whilst no single mutation 
defines the MDR phenotype, an accumulation of mutations leads to the resistance of multiple 
drugs. It is also postulated that the presence of classical resistance mutations maybe the 
gateway to resistance to other drugs.(7,35) 
There are 2 mechanisms resulting in drug resistant TB. (I) Primary resistance occurs by 
infection with an already drug resistant strain of M. tuberculosis. (II) Acquired (secondary) 
resistance occurs through inadequate treatment or poor treatment compliance that allows for 
the selection of drug resistant mutants within a patient’s body ie: after infection.(5,7,35) 
1.6.1.1 First Line Anti-TB Drugs 
Isoniazid 
INH was first introduced as an anti-TB drug in 1952 and, together with RIF forms the basis 
of the short-course regimen currently applied to the treatment of TB. INH is effective against 
metabolically active, replicating bacilli. INH is a pro-drug which is activated by the 
catalase/peroxidase enzyme, encoded by the katG gene. Once activated, INH inhibits mycolic 
acid synthesis via the NADH-dependent enoyl-acyl carrier protein (ACP)-reductase, encoded 
by the inhA gene. (7,8) The molecular basis of INH resistance is mediated by mutations in the 
katG, inhA gene or within the promoter region of the inhA gene. The most common resistance 
mechanism has been identified as the katG S315T mutation which leads to an inefficient 
INH-NAD product inhibiting the antimicrobial action of INH. This mechanism is associated 
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with high-level INH resistance in MDR isolates. (36–39) Mutations of the inhA promoter 
region, the most common at position, -15, results in an overexpression of inhA. This 
mechanism is associated with low-level resistance in INH mono-resistant isolates and has 
been implicated in cross resistance to a structural analogue, ethionamide. Mutations in the 
active region of the inhA gene result in a decreased affinity of the INH-NAD product.  Such 
mutations are less frequent. (40,41) A recent study reported that mutations occurring in the 
inhA regulatory region and coding region, resulted in high-level INH resistance and cross 
resistance to ethionamide. (42) Mutations in the dfrA gene have been recently implicated in 
resistance to INH. The 4R isomer of the INH-NADH product inhibits dihydrofolate 
reductase, encoded by dfrA. However, studies have failed to demonstrate a correlation 
between mutations in the dfrA and INH resistance.(43) Mutations in the promoter region of 
the ahpC gene were proposed as proxy markers for INH resistance. The ahpC gene in 
M.tuberculosis codes for an alkyl hydroperoxidase reductase enzyme responsible for 
resistance to reactive oxygen and nitrogen derivatives. Further analysis of such mutations 
revealed that this is compensatory mechanism for the reduction or loss of activity of the 
catalase-peroxidase system and does not confer INH resistance.(44) Studies have also 
reported mutations in the kasA, oxyR-ahpC and furA-katG in INH resistant isolates of 
M.tuberculosis. However, their exact role in mediating INH resistance is yet to be 
demonstrated. (45,46) More recently, a silent mutation in the mabA gene, resulting in the 
upregulation of inhA resulted in INH resistance.(47) 
Rifampicin 
RIF, a rifamycin derivative, was first introduced as an anti-TB drug in1972. RIF is one of the 
most effective anti-TB drugs, effective against actively metabolizing and slow-metabolizing 
bacilli, making the drug a key component of the current first line treatment regimen applied 
to the treatment of TB.(7,8,32,48) In M. tuberculosis, RIF binds to the β sub-unit of the RNA 
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polymerase, resulting in the inhibition of elongation of messenger RNA. Resistance to RIF is 
mediated by mutations clustered in codons 507-533 of the gene coding for the RNA 
polymerase β sub-unit, rpoB. This region is known as the RIF resistance-determining region 
(RRDR), the target of modern molecular based assays. Codons 526 and 531 bear the most 
common mutations associated with RIF resistance.(7,8,49–52) Mutations outside the RRDR 
have been reported in RIF resistant isolates. (53) Studies have also demonstrated a lack of 
alteration in the rpoB gene in a fraction of RIF resistant isolates, suggesting an alternate 
mechanisms of RIF resistance.(53) RIF mono-resistance is rare as RIF resistance occurs in 
conjunction with resistance to other drug, most commonly INH, making RIF targets a 
surrogate marker of the MDR phenotype. (54)Recent, whole genome sequence analysis 
demonstrated mutations in the rpoA and rpoC genes which encode the α and β’ subunits of 
the RNA polymerase as compensatory mechanisms in isolating bearing mutations in the rpoB 
gene. These mutations are associated with increased fitness and transmissibility of resistant 
strains.(11) 
Pyrazinamide 
PZA, a nicotinamide analogue, was first introduced as an anti-TB drug in 1952. PZA 
significantly reduced the duration of TB treatment to six months. A vital characteristic of 
PZA is its ability to inhibit semi-dormant bacilli located in acidic environments such as that 
of TB lesions. (32)PZA not only constitutes a part of the standard first line regimen to treat 
TB but is also key component of all current regimens undergoing evaluation in phase II and 
III clinical drug trials for the treatment of drug susceptible and resistant TB. (55)PZA is a 
pro-drug which is activated by the pyrazinamidase/nicotinamidase (PZase) enzyme, encoded 
by the pncA gene. (56,57)Once activated, pyrazinoic acid disrupts the bacterial membrane 
energetics thereby inhibiting membrane transport. PZA enters the bacterial cell by passive 
diffusion and is then converted into pyrazinoic acid. The pyrazinoic acid is the pumped out of 
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the bacterial cell by a weak efflux mechanism. In an acidic environment, the pyrazinoic acid 
is protonated allowing for reabsorption into the cell, resulting in cellular damage. (58) 
Pyrazinoic acid and its n-propyl ester have also been implicated in inhibition of fatty acid 
synthase I in M.tuberculosis. (59,60) It has been recently proposed that pyrazinoic acid is 
involved in inhibiting trans-translation in M.tuberculosis. Isolates lacking alteration in the 
pncA gene were reported to have mutations in the rpsA (ribosomal protein I) gene. 
Overexpression of rpsA has also been implicated in increased resistance to PZA.(61) 
However, there was no clear demonstration that mutations in rpsA was linked to PZA 
resistance.(62–64) Mutations in the pncA gene and its promoter region remains the most 
common mechanism mediating PZA resistance.(57)  The mutations identified within this 
gene are diverse, with 600 unique mutations in 400 positions reported to date.(55) A small 
proportion of resistant isolates lack mutations in the pncA gene, suggesting an alternate 
mechanism of resistance exists.(65) 
Ethambutol 
EMB was first introduced as an anti-TB drug in 1966 and remains a part of the current first 
line regimen applied to the treatment of TB. EMB is active against actively multiplying 
bacilli, disrupting the biosynthesis of the arabinogalactan in the cell wall. The embCAB 
operon encodes the mycobacterial arabinosyl transferase enzyme. Resistance to EMB is 
mediated via mutations in the embB gene.(66,67) Alteration on codon 306 is the most 
prevalent mechanism reported.(68,69) It was further reported that this mutation predisposes 
the isolate to develop resistance to other drugs and is not necessarily involved in EMB 
resistance.(70) Allelic exchange experiments have demonstrated that only certain amino acid 
substitutions led to EMB resistance.(71) Studies have shown that mutations in the 
decaprenylphosphoryl-B-D-arabinose (DPA) biosynthetic and utilization pathway genes 
(Rv3806c and Rv379), that occur simultaneously with mutations in embB and embC result in 
18 
 
a variable MIC range for EMB. This depends on the type of mutation that is present. 
Furthermore, this implies that the embB306 mutation results in varying degrees of EMB 
resistance but does not cause high-level EMB resistance on its own. (72)Resistance in 
approximately 30% of EMB resistant isolates lack alteration in the embB gene, suggesting an 
alternate mechanism of resistance.(7,8) 
Streptomycin 
STR, an aminocyclotol antibiotic was the first drug to be applied to the treatment of TB in 
1942. Due to the initial application of the drug as TB monotherapy, resistance rapidly 
emerged. (73)STR is active against slow growing bacilli and acts by irreversibly binding to 
the ribosomal protein S12 and 16S rRNA, which are the components of the 30S subunit of 
the bacterial ribosome. Through this interaction, STR blocks translation thereby inhibiting 
protein synthesis. (74,75)The main mechanism of resistance to STR is believed to be 
mediated via mutations in the rpsL and rrs genes, encoding the ribosomal protein S12 and the 
16S rRNA, respectively, accounting for approximately 60-70% of STR resistance.(76) 
Recently, reports of mutations in the gidB gene, encoding a 7- methylguanosine 
methyltransferase specific for methylation of the G527 in loop of the 16S rRNA, has been 
implicated in low-level STR resistance.(77–80) Whole genome analysis has also 
demonstrated a 130bp deletion within the gidB gene mediating STR resistance.(81) 
1.6.1.2 Second Line Anti-TB Drugs 
Fluoroquinolones 
Fluoroquinolones are potent bactericidal antibiotics currently applied as second line treatment 
for drug resistant tuberculosis. CIP and OFX, are older generation antibiotics, derivative of 
nalidixic acid.(82) New generation fluoroquinolones, MFX and gatifloxacin are currently 
under evaluation in clinical trials to be applied in first line regimens in an attempt to shorten 
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the duration of treatment. (4,34,83,84) This class of antibiotics target the DNA gyrase 
enzyme, thereby preventing transcription during cell replication. DNA gyrases are encoded 
for by the gyrA and gyrB genes. Resistance to the fluoroquinolones has been linked to 
mutations occurring in a conserved region known as the ‘quinolone resistance-determining 
region’ (QRDR) in the gyrA and gyrB genes.(7,85–87) Fluoroquinolone resistant strains of 
M.tuberculosis most frequently display mutations on codons 90, 91 and 94 of the gyrA gene. 
Mutations on codons 74, 88 and 91 have also been associated with fluoroquinolone 
resistance.(88–90) It has been reported that clinically significant resistance to ciprofloxacin 
and ofloxacin (MIC of 2µg/ml) is conferred by a single gyrase mutation, while double 
mutations in the gyrA or concomitant gyrA and gyrB mutations result in high-MICs. (90)A 
mutation detected on codon 95 of the gyrA is natural polymorphism that has no role in 
mediating fluoroquinolone resistance. (91) The complexity of fluoroquinolone resistance in 
M.tuberculosis has been demonstrated by the hyper susceptibility induced by the presence of 
mutations on codon 80 of the gyrA gene, especially when occurring with other resistance 
conferring mutations.(92) Efflux mechanisms have also been reported to mediate 
fluoroquinolone resistance.(93)  Mutations in the gyrB gene are rare.(7) 
Kanamycin, Amikacin, Capreomycin 
The aminoglycosides KAN and AMIK and the cyclic polypeptide, CAP are second line 
injectable agents currently applied to the treatment of drug resistant tuberculosis. Although 
these belong to different classes of antibiotics, they all exert their effect via the same target. 
(7,8)All three drugs are protein synthesis inhibitors, which act by binding to the bacterial 
ribosome resulting in a modification of the 16S rRNA structure. High level resistance to all 
three drugs has been associated with mutations in the 1400bp region of the rrs gene and 
additional resistance to CAP has been associated with polymorphisms of the tlyA gene. This 
gene codes for rRNA methyltransferase required for 2’-O-methylation of ribose in rRNA. 
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(77,94)The A to G polymorphism at position 1401 of the rrs gene is the most common 
molecular mechanism of resistance to all three drugs associated with approximately 70-80% 
of CAP and AMIK resistance and 60% of KAN resistance, globally.(9) A recent study 
reported increased fitness in clinical isolates bearing the rrs A1401G mutation. This was 
demonstrated by the difference in MIC between the laboratory engineered strains and clinical 
isolates with the same mutation. This increased fitness is thought to occur due to the presence 
of compensatory mutations that restore bacterial fitness.(95) Cross-resistance between KAN, 
AMIK and CAP has also been reported. Each of the drugs acts by inhibiting translation and 
therefore cross resistance between them is likely to occur. Full cross-resistance between KAN 
and AMIK was initially assumed, however, other studies have demonstrated discordant 
resistance patterns between these two agents.(96) It has also been reported that CAP 
resistance varies according to the level of resistance to KAN, and high-level resistance to 
KAN was associated with cross-resistance to CAP.(97) More recently, mutations reported in 
the promoter region of the eis gene resulted in low level resistance to kanamycin. The eis 
gene encodes an aminoglycoside acetyltransferase. Polymorphisms at positions -10 and -35 
of this gene resulted in an over expression of its protein product and low level kanamycin 
resistance. A study reported that 80% of the clinical isolates with low level resistance to KAN 
had genetic alterations in the promoter region of this gene.(98,99) 
Ethionamide 
Ethionamide (ETH), a derivative of isonicotinic acid is a structural analogue of isoniazid. 
ETH is a pro-drug which is activated by the mono-oxygenase enzyme, encoded by the ethA 
gene. Once activated, ETH inhibits mycolic acid synthesis during cell wall biosynthesis by 
inhibiting the enoyl-ACP reductase enzyme. Regulatory control of the ethA gene occurs via 
the transcriptional repressor, EthR.(100) Resistance to ETH is mediated by mutations in the 
etaA/ethA, ethR and inhA genes. Mutations in the inhA gene mediates co- resistance to both 
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INH and ETH.(101,102) A study has recently demonstrated the role of the mshA gene, 
encoding an enzyme essential to mycothiol biosynthesis as a target for ETH resistance using 
spontaneous INH- and ETH resistant mutants.(103) 
Para-Amino Salicyclic Acid 
PAS, an analogue of para-amino benzoic acid, was one of the first antibiotics used in the 
treatment of TB together with INH and STR. (28)PAS now forms a part of second line 
treatment regimens applied to the treatment of drug resistant TB. The mechanism of PAS 
resistance was only very recently elucidated. It is suggested that that PAS competes with p-
amino benzoic acid for the enzyme dihydropteroate synthase, inhibiting folate synthesis. The 
main mechanism mediating PAS resistance has been identified as mutations occurring in the 
thyA gene, accounting for 40% of PAS resistance. (104,105) A recent study demonstrated that 
mutations in the folC, encoding dihydrofolate synthase conferred resistance in clinical 
isolates resistant to the drug. (106) The T202A mutation initially associated with PAS 
resistance was found to be a phylogenetic marker associated with the Latin American (LAM) 
strain families rather that resistance to PAS. Mechanisms to fully elucidate PAS resistance 
are lacking.(107) 
Linezolid 
LIN, an oxazolidinone, is the first antibiotic in its class to be approved for the treatment of 
TB.(108) Recent studies have found that treatment outcomes with regimens containing LIN 
for complicated cases of MDR-TB are equal to or better than those reported for 
uncomplicated MDR-TB and better than those reported among patients treated for XDR-
TB.(109) LIN acts by binding to the V domain of the 50S ribosomal subunit, thereby 
inhibiting an early step in protein synthesis. (110) Resistance is mediated by mutations in the 
23 S rRNA (rrl) gene. A study reported 1.9% of LIN resistant isolates in a cohort of 210 
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MDR isolates.(110)  Analysis of in vitro selected mutants with mutations in the 23 S rRNA 
gene were associated with MICs of 16-32 mg/L while no mutations were detected in isolates 
with an MIC of 4-8 mg/L or in the LIN susceptible strains.(111) More recently, advances in 
sequencing technology identified mutations in the rplC gene, encoding the 50S ribosomal L3 
protein, in in vitro selected mutants and clinical isolates.(112) 
1.6.2 Efflux Mediated Resistance 
Efflux mechanisms are now recognised as a significant factor in antibiotic drug resistance of 
M.tuberculosis. These efflux systems are involved in expelling antibiotics from the bacterial 
cell, thereby allowing for the acquisition of resistance mutations in the bacterial genome. 
M.tuberculosis presents with one of the largest number of putative efflux pumps with 148 
genes coding for membrane transport proteins within its 4.4KB genome. The contribution of 
these efflux systems in acquiring multidrug resistance in M.tuberculosis has been 
demonstrated by numerous studies. (113,114) 
1.6.2.1 Mechanisms of Efflux Mediated Resistance 
The overexpression of efflux pumps is believed to mediate the build-up of resistance 
mutations, which confers high-level drug resistance allowing for M.tuberculosis to survive 
and persist at clinically relevant drug concentrations. The ability of the efflux pumps to 
extrude a diversity of compounds allows them to expel multiple drugs leading to the MDR 
phenotype.  (113,114) 
Efflux pumps have been classified into five superfamilies; the ATP-binding cassette (ABC), 
major facilitator super-family (MFS), resistance nodulation division (RND), small multidrug 
resistance (SMR) and multidrug and toxic-compound extrusion (MATE). The ABC 
superfamily is a primary transporter which utilizes ATP to pump to extrude drugs. The 
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remaining superfamilies are secondary transporters that utilize the trans-membrane proton 
motive force as a source of energy. (113,114) 
The ABC superfamily comprises of efflux systems responsible for the uptake and efflux of 
various compounds including; drugs, sugars, amino acids carboxylates and peptides. These 
transporters have been associated with resistance to INH, RIF, STR, EMB and the 
fluoroquinolone antibiotics. A significant ABC efflux mechanism encoded by the genes 
Rv2686c-Rv2687c-Rv2688c has been associated with an eight fold MIC increase for CIP 
when the genes are expressed as an operon in M.tuberculosis.(113–115) 
The MFS superfamily has been associated with resistance to almost all anti-tuberculosis 
drugs including INH, RIF, STR, EMB, the fluoroquinolones, aminoglycosides and 
ethionamide. The expression of MFS superfamily transporters operates under the regulatory 
control of inducer and repressor mechanisms that modulate gene expression. Significant MFS 
efflux mechanisms include the P55 pump, a multidrug efflux pump in M.tuberculosis 
encoded by Rv1410c. (113,114,116–118) 
Efflux pumps of the RND family are predominant in Gram-negative bacteria. A significant 
RND efflux mechanism in M.tuberculosis, encoded by the Mmpl7 gene, results in high level 
resistance to isoniazid.This phenomenon was reversed in the presence of efflux pump 
inhibitor (EPI) compounds.(113,114,119) 
Transporters belonging to the MATE superfamily have not been reported in M.tuberculosis 
and no significant SMR efflux mechanisms have been demonstrated in 
M.tuberculosis.(113,114,120) 
1.6.2.2 Efflux Pump Inhibitors 
Efflux pump inhibitors (EPIs) are compounds capable of restoring the activity of antibiotics 
independent of the level of resistance. The inhibitor-antibiotic combination decreases the 
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concentration of antibiotics expelled by efflux pumps, thus decreasing the MIC of the 
antibiotic. The use of EPIs has been considered as an adjuvant in TB treatment and has the 
potential to reduce the duration of TB treatment. (11,114) 
Thioridazine 
Thioridazine (THIO), a phenothiazine compound used as an antipsychotic drug has been 
explored in patients infected with M.tuberculosis, with encouraging outcomes. The 
application of THIO as an adjuvant in TB treatment demonstrated cure in 10/12 patients with 
XDR TB and is currently applied to the treatment of drug resistant TB on the basis of 
compassionate use. (121) 
The phenothiazines are calcium channel blockers that prevent calcium binding to calcium 
dependent enzymes. It has been demonstrated that THIO enhances the killing on newly 
phagocytosed bacteria and MDR and XDR TB. THIO acts by inhibiting the transport of 
calcium and potassium from the phagolyosome to the cytoplasm, resulting in an increased 
concentration of H+ to activate hydrolases that lead to the degradation of phagocytosed 
bacteria.(122,123) 
The utility of THIO in the management of newly diagnosed TB is reinforced by observations 
that this agent enhances the in vitro activity of RIF against resistant strains of M.tuberculosis. 
RIF resistance decreases significantly in the presence of EPIs. These observations suggest 
that the use of THIO may permit a reduction in the current dosage of anti-tuberculosis drugs 
and may potentially restore the activity of the current standard treatment regimen. Another 
prospective benefit of THIO is that genetic mutations that result in drug resistance are not 
expected as calmodulin, the calcium transport protein to which THIO binds and inactivates, is 




Verapamil (VERA) is a calcium channel blocker currently applied to various disorders that 
include angina, hypertension and cardiac disorders. It has been demonstrated that VERA has 
the greatest ability to inhibit efflux of ethidium bromide as compared to THIO. VERA is also 
known to interfere with the proton motive force which is the energy source of most efflux 
pumps. VERA has demonstrated a significant reduction in the MICs for INH of up to 4 folds 
in M.tuberculosis isolates with the resulting MIC in the presence of verapamil similar to the 
corresponding wild type and INH susceptible isolates.(125,126) 
Reserpine 
Reserpine (RES), like verapamil is a calcium channel blocker. RES is a natural plant 
metabolite that was utilized as a hypertensive drug. RES demonstrated activity against the 
pyrazinoic acid pump, increasing the susceptibilities of M.tuberculosis isolates to PZA. It has 
also demonstrated activity in decreasing MICs of LIN and EMB. Due to the carcinogenicity 
associated with the compound, it is no longer utilised in treatment protocols.(126) 
1.6.3 Alternate Mechanisms of Resistance 
DNA Repair Systems 
The role of DNA repair systems in antibiotic resistance is of growing interest. DNA repair 
systems are believed to influence the type and frequency of mutations that are involved in 
drug resistance. Mutations within the genes that code for repair systems, result in inefficient 
repair systems that allow for the development of further mutations. This provides the 
pathogen with a selective advantage over its host.(127,128) This was demonstrated in the 
Beijing strain family, where mutations in the antimutator (mut) genes were associated with 
increased ability to acquire resistance. The role of these systems requires further elucidation. 
(11,129,130) 
Increased Mutation Rates 
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An increase in mutation rates has been in observed in M.tuberculosis when exposed to sub-
inhibitory levels of antibiotics. This effect is most predominant in antibiotics that target 
DNA.(131) The fluoroquinolone antibiotics serve as a prime example. They act by binding to 
DNA gyrases. It has been demonstrated that M.tuberculosis has the ability to induce breaks in 
its double-stranded DNA resulting in transcriptional changes in genes that encode vital DNA 
repair mechanisms such as the SOS repair system. (11,132,133) 
The Role of Compensatory Mutations 
It has been postulated that resistance mutations bear a fitness cost to the bacterium. However, 
recent studies have demonstrated the presence of secondary mutations that act as 
compensatory mechanisms for the impaired fitness of the pathogen.(11) Sherman et al. 
demonstrated this phenomenon in INH resistant isolates of M.tuberculosis with an inactivated 
katG gene. The absence of katG catalase-peroxidase activity resulted in mutations in the 
regulatory region of the ahpC (alkyl hydroperoxidase reductase) gene, leading to 
overexpression of this gene. Mutations of the ahpC gene are believed to be compensatory for 
the loss of katG activity.(134) More recently, whole genome analysis showed that mutations 
occurring in RNA polymerases rpoA and rpoC were compensatory for the loss of fitness 
mediated by mutation in the rpoB gene in RIF resistant isolates.(135,136) A recent report also 
demonstrated varying levels of CAP resistance amongst A1401G laboratory mutants and 
clinical isolates bearing the same mutation, implying a possible role of compensatory 
mutations that restore fitness in isolates bearing resistance mutations. (95) 
1.7 Problem Statement 
Antibiotic therapy remains the key tool in the control of TB and understanding the 
mechanisms of drug resistance in M.tuberculosis is a significant component of the disease 
control strategy. Mutations in genomic drug targets have been identified as the principal 
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mechanism mediating antibiotic resistance. However, recent reports demonstrate the interplay 
of additional mechanisms. The role of the efflux pumps is believed to play a significant role 
in mycobacterial drug resistance. However, this mechanism has never been fully elucidated in 
our setting. This study, through amplification and sequencing of genes associated with 
resistance to first, second and third line drugs and by investigating the role of putative efflux 
pumps provides additional novel data on antibiotic resistance mechanisms in M.tuberculosis. 
1.8 Aims 
The aim of the study was 2-fold: 
1. To characterize genetic mutations associated with resistance to anti-TB drugs and 
correlate these to the MIC of anti-TB drugs in clinical isolates of M.tuberculosis. 
2. To investigate the role of efflux transporters mediating drug resistance in clinical 
isolates of M.tuberculosis. 
1.9 Objectives and Thesis Layout 
Layout of this thesis with specific objectives of the study:  
 To determine the MICs of the key first line drugs; INH, RIF and EMB and to amplify 
and sequence the genes associated with resistance to each of the drugs: inhA, katG, 
rpoB and embB (Manuscript I, Chapter 2). 
 To sequence the pncA gene for mutations associated with resistance to PZA 
(Manuscript I, Chapter 2). 
 To determine the MICs for STR and sequence the rrs 500 region, rpsL and gidB genes 
(Manuscript II, Chapter 3). 
 To determine the MICs of the fluoroquinolones: CIP, OFLOX and MOXI and 
sequence the gyrA and gyrB genes (Manuscript III, Chapter 4). 
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 To determine the MICs of the second line injectable drugs; KAN, AMIK and CAP 
and to sequence the rrs, thyA and eis genes (Manuscript IV, Chapter 5)  
 To sequence the rrl and thyA genes associated with resistance to LIN and PAS 
(Manuscript V, Chapter 6) 
 Determine the MICs in presence of EPIs (Manuscript VI, Chapter 7). 
 Summary of Findings (Chapter 8) 
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Abstract 
Background: In South Africa, drug resistant tuberculosis is a major public health crisis in the 
face of the colossal HIV pandemic.  
Methods: In an attempt to understand the dynamics of drug resistance in our setting, we 
analysed the rpoB, katG, inhA, pncA and embB genes associated with resistance to key drugs 
used in the treatment of tuberculosis in clinical isolates of Mycobacterium tuberculosis in the 
KwaZulu-Natal province. 
 Results: Classical mutations were detected in the katG, inhA and embB genes associated with 
resistance to isoniazid and ethambutol. Diverse mutations were recorded in the multidrug 
resistant (MDR) and extensively drug resistant (XDR) isolates for the rpoB and pncA gene 
associated with resistance to rifampicin and pyrazinamide.  
Conclusions: Multiple drug resistance mechanisms in the MDR-TB isolates suggests that the 
strains emerged separately and acquired resistance mutations independently. The similarity of 
mutations detected in the XDR-TB strains confirms reports of the clonality of the XDR 
epidemic. The successful dissemination of the drug resistant strains in the province 




Keywords: Drug-resistance, first-line drugs, multi-drug resistant-TB, extensively drug-
resistant-TB, clonality 
Background 
Tuberculosis (TB) remains one of the greatest public health concerns of our time, exacerbated 
by co-infection with human immunodeficiency virus (HIV) and drug resistance. In its latest 
global TB report in 2014, the world health organization (WHO) estimated that 3.5% of new 
cases and 20.5% previously treated patients have multi-drug resistant (MDR) TB; i.e. 
resistance to isoniazid (INH) and rifampicin (RIF). Of these cases, 9% have extensively drug 
resistant (XDR) TB. XDR-TB strains display resistance to INH, RIF and additional resistance 
to a fluoroquinolone antibiotic and one of the three injectable second line agents: amikacin 
(AMIK), kanamycin (KAN) and capreomycin (CAP). [1] 
Despite the implementation of therapeutic regimes combining INH, RIF, Ethambutol (EMB) 
and pyrazinamide (PZA)[2], the escalation of MDR-TB strains has compromised the utility 
of this drug combination. The morbidity and mortality rates associated with drug resistant TB 
is several times higher than drug susceptible forms.[1] Treatment of drug resistant TB is 
further complicated by the decreased efficacy and higher toxicity associated with the second 
line drugs as well as the inability to provide early diagnostic data to guide treatment. [3] 
Conventional drug susceptibility testing relies on mycobacterial culture methods, providing 
results after weeks or months. Molecular based diagnostics, such as the GeneXpert MTB/RIF 
(Cepheid) assay that do not rely on culture, are central to the future management of drug 
resistant tuberculosis. Their accuracy, however, is dependent on the association between a 
specific gene mutations and phenotypic drug susceptibility results. Drug susceptibility testing 
to second-line anti-TB drugs are more complicated that first line drugs. This is mainly due to 
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the technical difficulty associated with drug susceptibility testing for second line agents and 
the geographic diversity of the associated resistance conferring mutations. [4] 
To date, the genes associated with resistance to the first line drugs in Mycobacterium 
tuberculosis have been identified based on the mode of action of each of the drugs and their 
demonstrated association with drug resistance. These include ropB (RIF), katG and inhA 
(INH), pncA (PZA) and embB (EMB). [5, 6] 
In the study described in this report, we analysed mutations in the ropB, katG, inhA, pncA and 
embB genes and their association to resistance to the key first line antimicrobials in clinical 
isolates from the KwaZulu-Natal (KZN) province of South Africa. 
Methods 
M. tuberculosis Clinical Isolates 
M. tuberculosis clinical isolates were selected from the storage collection of the Infection 
Control laboratory, University of KwaZulu-Natal. The isolates were from sputum specimens 
obtained from patients presenting to the Church of Scotland Hospital in the Tugella Ferry 
region of KZN, South Africa from 2005 to 2009. At initial isolation, the drug susceptibility 
profiles of the isolates were established in our laboratory using the 1% proportion method. [7] 
Sixty isolates were selected for the study: 10 drug susceptible (DS), 20 multi-drug resistant 
(MDR-TB) and 30 extensively drug resistant (XDR-TB). The H37Rv laboratory strain was 
included as a control. Ethical approval for the study was obtained from Biomedical Research 
Ethics Committee of the University of KwaZulu-Natal (BREC 247/09). 
Determination of the Minimum Inhibitory Concentration (MIC) 
MIC was established using a multipoint inoculation technique on Middlebrook 7H10 agar 
medium supplemented with oleic acid-albumin-dextrose-catalase (OADC). Test plates 
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contained INH, RIF and EMB at concentrations of 0.125; 0.25; 0.5; 1; 2; 4; 8; 16; 32; 64 and 
128 mg/L. The plates were seeded with M.tuberculosis at an optical density (600nm) reading 
of 1. Test plates were incubated at 37ºC for 21 days in the presence of 5% CO2.  The MIC of 
an isolate was recorded as the lowest antibiotic concentration that inhibited growth of the 
organism. Resistance to INH, RIF and EMB was defined as concentrations of 0.2, 1.0 and 5.0 
mg/L respectively, in accordance to WHO guidelines. [8] Isolates were tested in triplicate to 
ensure test accuracy and reproducibility. Due to the technical difficulty associated with 
conducting susceptibility testing with PZA, MICs were determined for the drug. 
Genomic DNA Extraction & Amplification 
Genomic DNA was extracted from cultures grown on Middlebrook 7H11 media using the 
CTAB-NaCl (Cetyl-trimethyl-ammonium Bromide-Sodium Chloride) method, as described 
previously.[9] The integrity and concentration of the DNA was determined using a NanoDrop 
2000c spectrophotometer (Thermo Scientific). PCR amplification assays were carried out for 
the inhA, katG, rpoB, pncA and embB genes. Primers for each of the genes were selected 
from published literature or designed using Primer3 design software.[10] The Expand Hi 
Fidelity PCR kit (Roche) was used in accordance to the guidelines set out by the 
manufacturer. Table 2.1 contains specific annealing temperatures and primer sequences used 
for amplification. 
DNA Sequencing & Analysis 
Prior to sequencing, the quality of PCR amplicons were determined on a 1% agarose gel. 
Amplicons were purified using the Invitrogen PureLink PCR purification kit (Applied 
Biosystems) and sequenced using ABI Prism Big Dye Terminator cycle sequencing kit V3.1 
(Applied Biosystems) together with the forward primers selected for PCR amplification. 
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Nucleotide sequences were aligned to the H37Rv reference strain using Genious V5.5.7 
(Biomatters) sequence analysis software.[11] 
Genotyping 
The genotypes of the isolates were established using the IS6110 restriction fragment length 
polymorphism (RFLP) method, as described previously. [12] 
Results 
RFLP Analysis 
RFLP analysis revealed that most of the DS isolates belonged to the Beijing family of strains. 
Three DS isolates had a unique profile and 1 isolate was a variant of the F11 strain family. 
The F28 strain family was the predominant genotype of the MDR-TB isolates, whereas the 
remaining isolates belonged to the F15/LAM4/KZN (KZN) strain family. One MDR-TB 
isolate recorded a unique profile and 1 was a variant of the F28 strain family. All of the 
XDR-TB isolates analysed in the study belonged to the KZN strain family. Genotypes, 
mutations and associated phenotypes are shown in tables 2.2 and 2.3. 
rpoB mutations and RIF resistance 
Of the sixty M.tuberculosis isolates initially selected, 2 MDR and 3 XDR-TB isolates failed 
multiple attempts at amplification of the rpoB gene and were excluded from further analysis. 
Majority (73%) of the RIF resistant isolates had at least 1 mutation in the rpoB gene, while 5 
RIF resistant (3 MDR-TB, 2 XDR-TB) isolates had no alteration within the rpoB gene.  The 
rpoB mutations were of various types:  (1) A→G substitution on codon 435 (A1304G, 
D435G); detected in 3 XDR-TB isolates with an MIC range of 64-128 mg/L, belonging to the 
KZN family of strains.  (2) T→ C substitution on codon 452 (T1355C, L452P); detected in 1 
MDR-TB isolate of the KZN family strain family with an MIC of 8 mg/L. (3) C→T 
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substitution on codon 450 (C1349T, S450L); detected in 7 MDR-TB isolates which belonged 
to the KZN and F28 strain families and 1 XDR-TB isolate of the KZN strain family with an 
MIC range of 32-128 mg/L. Double mutants included (4) the D435Y together with an C→ A 
substitution on codon 454 (C1360A, P454T); detected in 1 MDR-TB isolate of the KZN 
strain family with an MIC of 128 mg/L. (5)  A → T substitution on codon 445 (A1334T, 
H445L) and a G → C substitution on codon 491 (G1473C, I491M); detected in 1 MDR-TB 
isolate, a variant of the F28 strain family with an MIC of 128 mg/L.  (6) The S450L and 
L452P detected in 2 MDR-TB isolates of the KZN and F28 strain families with an MIC of 64 
mg/L; (7) the D435G and L452P detected in 22 XDR-TB isolates belonging to the KZN 
strain family with an MIC range of 32-128 mg/L. (8) The S450L and a T → C substitution on 
codon 564 (T1690C, Y564H), detected in 2 MDR-TB isolates of the KZN strain family with 
an MIC of 128 mg/L. No mutations were detected in any of the DS isolates screened. The 
rpoB mutations, with the corresponding MIC and genotypes of the isolates are shown in table 
2.2. 
inhA; katG mutations and INH resistance 
No mutations were detected in the inhA gene or its promoter region amongst the isolates 
screened in the study. The katG mutations were of 3 types, (1) G→T substitution on codon 
473 (G1388T; no amino acid alteration); detected in 5 DS isolates, all belonging to the 
Beijing family of strains. (2) G→C substitution on codon 315 (G944C, S315T); detected in 
all of the MDR and XDR-TB isolates studied. The MIC range of the isolates was 4-16 mg/L. 
The mutation was detected across all genotypes detected in the study. (3) One MDR-TB 
isolate, unique in its genotype had double mutations within the katG gene. In addition to the 
S315T mutation, an A→C substitution on codon 468 (A1343C, N468A) was detected, 
associated with MIC of 16 mg/L.  
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The remaining DS isolates had no alteration in the katG gene.  
pncA mutations and PZA resistance 
Of the sixty M.tuberculosis isolates initially selected, 1 MDR and 2 XDR-TB isolates failed 
multiple attempts at amplification of the pncA gene and were excluded from further analysis. 
pncA gene mutations were of 3 types, (1) T→G substitution on codon 34 (T100G, Y34D); 
detected in 6/15 MDR-TB  isolates, of which 5 belonged to the F28 family and 1 to the KZN 
family of strains. (2) T→G substitution on codon 139 (T416G, L139G); detected in 2/15 
MDR-TB isolates, belonging to the KZN family of strains. (3) Insertion of a cytosine at 
position 457, present in 1 MDR-TB and all the XDR-TB isolates screened, all belonging to 
the KZN strain family, resulting in a frameshift. The remaining MDR-TB isolates and DS 
isolates had no alteration in the pncA gene. 
embB mutations and EMB resistance 
The embB mutations were of 2 types, (1) A→G substitution on codon 306 (A916G, M306V); 
detected in 14 MDR-TB and 30 XDR isolates, associated with an MIC range of 2-16 mg/L. 
The mutation was detected across all genotypes of the study. (2) C→A substitution on codon 
506 (C1489A, Q506K); detected in 2 MDR-TB isolates, belonging to the F28 family of 
strains and associated with an MIC of 16 mg/L. The DS isolates had no alteration in the embB 
gene.  
Mutations of the inhA, katG, embB and pncA gene, MIC and associated genotypes are shown 
in table 2.3. 
Discussion 
In this study, we report on the dynamics of drug resistance amongst clinical isolates from 
KwaZulu-Natal, South Africa. South Africa ranks amongst the top ten high burden countries 
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of drug resistant tuberculosis worldwide. The overall incidence rate in the KwaZulu-Natal 
province alone currently exceeds the incidence rates for all types of TB in some low 
incidence countries, like the USA.[13] In an attempt to understand the molecular basis of 
drug resistance in our setting, we sequenced the ropB, inhA, katG, pncA and embB genes 
associated with resistance to key drugs used in the treatment of tuberculosis. 
Analysis of the inhA, katG and embB genes demonstrated classical mechanisms that have 
been associated with resistance to INH and EMB.[5, 6] No mutations were detected in the 
inhA gene or its promoter region in the isolates screened. This is in keeping with previous 
reports.[14] Common inhA mutations that have been reported occur in the inhA promoter 
region at position -15, its correlation, however, is strongest with INH mono-resistant isolates 
or isolates with low-level INH resistance.[5, 6] However, a recent study demonstrated that 
double mutations in the inhA gene, in the promoter and coding regions, resulted in high-level 
INH resistance.[15] A large number of RIF resistant isolates bear mutations in the inhA and 
its promoter region making these mutations high predictors of RIF resistance, despite being 
absent in a subset of INH resistant isolates. 
The main mechanism mediating INH resistance in the isolates studied is the katG S315T 
mutation that was detected in all the MDR and XDR-TB isolates. Numerous reports have 
found this mutation to be the most common mutation associated with INH resistance. One 
MDR-TB isolate with unique genotype had double mutations in the inhA gene:the S315T 
mutation occurred in conjunction with the N468A mutation. The double mutant did not 
record a higher MIC as compared to the other isolates bearing the S315T mutation only. The 
N468A appears to be novel, but may represent a natural polymorphism or phylogenetic 
marker of the unique genotype of the isolate. The G1388T mutation detected in the 5 DS 




Approximately 96% of RIF resistance is attributed to mutations contained in an 81bp hot-spot 
region known as the RIF resistance determining region (RRDR) which encompasses codons 
507-533 of the rpoB gene.[5, 6] Mechanisms of resistance for the MDR and XDR-TB isolates 
varied in the case of RIF resistance, despite the MICs falling within a similar range. Various 
mutation types were described amongst the MDR-TB isolates. The S450L (corresponding to 
codon 531 in E.coli) mutation was the most common, accounting for resistance in 7 MDR-TB 
isolates, in keeping with various reports. Four MDR-TB Isolates had the S450L mutation 
together with L452P (corresponding to codon 533 in E.coli) or the T564H mutation. One 
MDR-TB isolate had the L452P mutation only. One isolate had the H445L (corresponding to 
codon 526 in E.coli) and the I491M mutation. To the best of our knowledge, the I491M and 
T564H mutations are novel and appear to be involved in mediating RIF resistance.  
The main mutation mediating RIF resistance in the XDR-TB isolates was the D435G 
mutation together with the L452P mutation. This was detected in all the XDR-TB isolates 
and 1 MDR-TB isolate. Three isolates had the D435G mutation only and one isolate had the 
S450L mutation. Although the mutations and genotypes of the isolates were diverse, all 
mutations correlated with high level RIF resistance. Interestingly, the MDR and XDR-TB 
isolates both had mutations on the codon 435 but each resulted in different amino acid 
substitutions.  Similar findings were described for KZN MDR and XDR-TB isolates in a 
study by Ioger et al. [14]analysing the whole genome sequences of drug resistant isolates 
KZN strain family. The main mechanism mediating resistance in the KZN MDR-TB isolate 
was attributed to the D435Y mutation and the D435G and L452P mutations in the KZN 
XDR-TB isolates. The study only analysed the KZN strain family.[14] Our study shows a 
greater diversity in the MDR-TB RIF resistance mechanisms and the isolates represented 
various strain families. In our study, the mutation on codon 435 was responsible for 
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resistance in most of the MDR-TB isolates. In contrast, Ioger et al. [14] reported that this 
mutation was only responsible for 9% of RIF resistance. [14] 
Resistance to PZA, as in the case of RIF was represented by diverse mutations in the MDR-
TB and XDR isolates. The MDR-TB isolates had a mutation either on codon 34 (nucleotide 
100) or codon 139 nucleotide 416), while XDR-TB isolates had an insertion of a cytosine at 
position 457, leading to a frameshift in the amino acid translation. The insertion was also 
detected in one MDR-TB isolate, possibly with a higher level of resistance to PZA. Due to 
technical difficulty associated with PZA susceptibility testing, no MICs were done for the 
drug. Instead, we sought to identify mutations in the MDR and XDR-TB groups and compare 
them with published literature. Mutations at position 100 have been described in isolates in 
Japan and Peru while mutations at position 416 have been reported South Africa, Thailand, 
China, USA, Portugal, Spain and Singapore. [16–24] The insertion at position 457 has been 
described in isolates from Brazil. [25] 
Mutations within the pncA gene are highly diverse, with 600 unique mutations at 400 
different positions reported to date.[24] In keeping with this diversity, the study by Ioger et 
al. showed different mechanisms of PZA resistance in the MDR and XDR-TB isolates from 
the KZN strain family as compared to the mechanisms described in this report.[14] This 
highlights the difficulty associated with detection of PZA resistance. The diversity of the 
mutations detected in the isolates vary greatly, making it impossible to apply to molecular 
diagnostic assay. PZA susceptibility testing poses a further challenge. The PZase enzyme 
required for the conversion of PZA to its active form is only functional at an acid pH, making 
it difficult to test the drug using conventional media. With a prevalence of approximately 
60.5% in patients with confirmed MDR-TB, PZA resistance testing is of utmost importance 
as PZA forms an integral role in current multidrug regimens and is also a key component of 
new treatment regimens undergoing evaluation in phase II or III clinical trials. [24] 
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A few isolates resistant to RIF and PZA did not display any mutations in the related genes. 
This phenomena has been previously described.[5, 6] This suggests that alternate resistance 
mechanisms may exist that remain to be identified. The differences in resistance mechanisms 
in the MDR and XDR-TB isolates suggest that the strains emerged separately and acquired 
resistance mutations independently. This is against the premise that the XDR phenotype had 
evolved directly from the MDR phenotype.  
Conclusion 
The multiple MDR-TB strains circulating in the KZN province suggests that the MDR-TB 
strains are evolving and spreading by transmission, demonstrated by the diversity of 
resistance mechanisms in the isolates. In contrast, the XDR-TB strains have disseminated by 
clonal expansion, demonstrated by the high level of similarity in the mutations detected. The 
successful dissemination of these resistant strains demonstrates that the resistance mutations 
come with a lower/no fitness cost than previously assumed; compensatory mechanisms might 
play a role in maintaining the fitness of this pathogen. The results of the current study 
underscores the need for novel assays to rapidly detect resistance to all drugs in order to 
effectively guide individualised treatment. 
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Table 2.1: Primer sequences and annealing temperatures used for PCR and sequencing. 











rpoB F TGTTGGACATCTACCGCAAG 54◦C 
 
916bp Rifampicin * 
rpoB R CGAGACGTCCATGTAGTCCA 
 
inhA 
inhA F CTACATCGACACCGATATGAC 55◦C 
 
700bp Isoniazid [26] 
inhA R GACCGTCATCCAGTTGTAG 
 
katG 
katG F GGTCGACATTCGCGAGACGTT 57◦C 
 
987bp Isoniazid [27] 
katG R TTGTTCCTGCGACGCATCGTG 
 
pncA 




pncA R GCTTTGCGGCGAGCGCTCCA 
 
embB 
embB F AAGCTGGCGCACCTTCAC 
55◦C 
 
833bp Ethambutol * 
embB R  ATAGCGCGGTGATCAAA
AA 
 





















D435G 64- 128 3  XDR KZN 
S450L  32-128 7 MDR 
1 XDR 
F28 / KZN 
  L452P 8 1 MDR KZN 
D435Y & P454T 128 1 MDR KZN 
H445L & I491M 128 1 MDR F28V 
S450L & L452P 64 2 MDR F28/ Unique 
D435G & L452P 32-128 22 XDR KZN 
S450L & T564H 128 2 MDR F28/KZN 













Table 2.3: Mutations of the inhA, katG, embB and pncA gene, associated MICs, phenotypes 
and genotypes. 









inhA None 0.125-16 All study isolates Various 
katG 
G1388T <0.125 5 DS Beijing 






16 1 MDR Unique 
PZA pncA 
Y34D * 6 MDR F28/ KZN 
L139G * 2 MDR KZN 









Q506K 16 2 MDR F28 












Streptomycin resistance in the F15/LAM4/KZN strain of Mycobacterium tuberculosis is 
mediated by lineage-specific alteration of the gidB gene.  




Widespread streptomycin resistance in Mycobacterium tuberculosis, resulting from the 
historical application of the drug as tuberculosis monotherapy has impelled policymakers to 
exclude the drug from treatment regimens. Streptomycin resistance is believed to be mediated 
via mutations in the rpsL, rrs and gidB genes. This study aimed to investigate the 
mechanisms of streptomycin resistance in clinical isolates from KwaZulu-Natal, South Africa 
and to determine if the drug has any further clinical relevance in tailored treatment and 
retreatment regimens. A mutational analysis was conducted on the rpsL, rrs and gidB genes 
by PCR amplification and sequencing. MIC’s for streptomycin were determined using a 
multipoint inoculation technique on Middlebrook 7H10 medium and linked to the mutation 
profiles and IS6110 RFLP genotype pattern of clinical isolates. The circulating MDR and 
XDR F15/LAM4/KZN strains had a rare 130bp deletion in the gidB locus resulting in 
streptomycin resistance. The K43R rpsL mutation was linked to the F28 family in the MDR-
TB isolates. The gidB L16R mutation linked to KZN family was detected in all KZN strains 
whilst the E92D mutation associated with the Beijing lineage was detected in the F28 strains. 
None of the mutations could be linked to the phenotypic level of streptomycin resistance that 
the isolates displayed. A 130bp deletion in the gidB gene in all MDR-TB and XDR-TB 
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strains of the F15/LAM4/KZN family, is the most significant mechanism mediating 
streptomycin resistance in the province.  
Introduction 
The discovery of streptomycin (STR), an aminoglycoside antibiotic, was a turning point in 
the treatment of tuberculosis (TB) in the 1940’s. STR was the first chemical compound 
effective in the treatment of TB. Historically, the drug was applied as TB monotherapy and 
early studies indicated a decline treatment response after three months of treatment, resulting 
from the rapid development of drug resistance when a single drug is used for the treatment of 
TB. In the 1950’s, several new anti-TB drugs were developed and applied as combination 
therapy. (Zumla et al., 2013) STR remained an integral part of treatment regimens, playing an 
important role in combination and re-treatment therapy for the disease. However, the high 
rates of STR resistance, increased toxicity associated with the drug and decreased efficacy in 
comparison to succeeding drugs, lead to a gradual decrease in the application of the drug in 
TB treatment.(Jagielski et al., 2014; Zumla et al., 2013)  
In South Africa, the first line treatment for TB includes a combination of isoniazid, 
rifampicin, pyrazinamide, and ethambutol during the intensive phase of treatment, followed 
by isoniazid and rifampicin in the continuation phase. STR has been  excluded , from all 
treatment protocols since 2014, mainly due to the emergence and spread of drug resistant 
strains of Mycobacterium tuberculosis.(National Department of Health, 2014) 
The mechanism of action of STR in M. tuberculosis, involves irreversible binding to the 
ribosomal protein S12 and 16S rRNA, which are the components of the 30S subunit of the 
bacterial ribosome. Through this interaction, STR blocks translation thereby inhibiting 
protein synthesis. The main mechanism of resistance to STR is believed to be mediated via 
mutations in the rpsL and rrs genes, encoding the ribosomal protein S12 and the 16S rRNA, 
respectively. Amino acid substitutions in the S12 protein affect the affinity of STR binding 
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by altering the higher-order structure of 16S rRNA. Mutations occurring within the16 S 
rRNA gene itself, results in a decreased affinity for STR. Mutations in the rpsL gene have 
been associated with a high-level of STR resistance, whereas mutations described in the rrs 
gene have been shown to confer lower levels of resistance (Jagielski et al., 2014; Okamoto et 
al., 2007; Verma et al., 2014)  
More recently, reports of mutations in the gidB gene, encoding a 7- methylguanosine 
methyltransferase specific for methylation of the G527 in loop of the 16S rRNA, has been 
implicated in low-level STR resistance (Da Silva and Palomino, 2011; Jagielski et al., 2014; 
Okamoto et al., 2007; Spies et al., 2011, 2008; Verma et al., 2014; Wong et al., 2011). The 
G527 site lies within the 530 loop, a hotspot region for STR resistance. The S12 protein 
binding site lies in close proximity to the 530 loop and assists in proofreading during 
translation. Lack of methylation by gidB, in the presence of mutations mediates STR 
resistance. (Jagielski et al., 2014; Okamoto et al., 2007; Verma et al., 2014). Reports on the 
deletion of the gidB gene in Salmonella species has been implicated with decreased bacterial 
fitness and has been associated high-level resistance to aminoglycoside antibiotics. (Mikheil 
et al., 2012) 
 The rapid determination of drug resistance patterns in clinical isolates of M.tuberculosis is an 
essential prerequisite for optimal treatment and decreased transmission of the disease. 
Currently, screening for mutations in well-defined genes associated with drug resistance is 
the most promising tool.(Da Silva and Palomino, 2011) In the case of STR, the association 
between mutations in the rpsL and rrs genes and drug-resistant phenotypes has been well 
characterized, whilst reports of mutations in the gidB gene have been inconsistent (Da Silva 
and Palomino, 2011; Okamoto et al., 2007; Palomino and Martin, 2014). Furthermore, STR 
resistance mutations have been reported to vary depending on the population and 
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geographical area studied. (Dobner et al., 1997; Jagielski et al., 2014; Katsukawa et al., 1997; 
Ramaswamy et al., 2004; Shi et al., 2007; Tudo et al., 2010) 
The aim of this study was to investigate the role of mutations in the rpsL, rrs, and gidB genes 
in clinical isolates of M. tuberculosis from KwaZulu-Natal, South Africa. 
Materials and Methods 
Clinical isolates 
Clinical isolates for the study were obtained from the culture collection of the Infection 
Control Laboratory, University of KwaZulu-Natal, South Africa. Stored isolates were 
cultured onto Middlebrook 7H11 medium supplemented with oleic acid-albumin-dextrose-
catalase (OADC). A total of 60 isolates were included in the study: 10 drug susceptible (DS), 
20 multi-drug resistant (MDR-TB) and 30 extensively drug resistant (XDR-TB). The H37Rv 
laboratory reference strain was included as an experimental control. The primary isolation, 
species identification, genotyping and drug susceptibility testing were established in previous 
studies conducted in our laboratory, using standard mycobacterial protocols.  The study was 
approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal 
(BREC 247/09).  
Minimum Inhibitory Concentration Determination 
STR MIC’s were established using a multipoint inoculation method on Middlebrook 7H10 
agar medium supplemented with OADC. Plates containing STR at concentrations of 0.125; 
0.25; 0.5; 1; 2; 4; 8; 16; 32; 64 and 128 mg/L were inoculated with bacterial cultures grown 
to an optical density (600nm) reading of 1 . Plates were then incubated in a CO2 enriched 
atmosphere at 37ºC for 21 days.  The MIC of an isolate was recorded as the lowest antibiotic 
concentration that resulted in a complete inhibition of growth. Resistance to STR was defined 
at a break point concentration of 2 mg/L, according to guidelines set out by WHO (World 
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Health Organisation, Geneva, 2009). All isolates were tested in triplicate to ensure test 
accuracy and reproducibility.  
DNA Extraction  
Genomic DNA was extracted from M.tuberculosis cultures using the CTAB-NaCl (Cetyl-
trimethyl-ammonium Bromide-Sodium Chloride) method (Van Soolingen et al., 1991). A 
NanoDrop spectrophotometer was used to estimate the quantity and purity of the isolated 
DNA. 
PCR Amplification & Sequencing Analysis 
PCR amplification assays were conducted for rpsL, rrs and gidB genes and sequenced to 
determine genetic alteration. The oligionucleotide primers for each gene (Table 1) was 
selected from published literature and applied to the Expand High Fidelity PCR kit (Roche) 
in accordance to the kit guidelines with annealing temperatures of 56◦C for the rrs gene and 
55◦C for rpsL and gidB genes. The quality and integrity of the PCR amplicons was analysed 
using agarose gel electrophoresis and purified using the Invitrogen PureLink PCR 
purification kit (Applied Biosystems). Direct single stranded sequencing of the amplicons 
was performed using ABI Prism Big Dye Terminator cycle sequencing kit V3.1 (Applied 
Biosystems) with the forward primers used for PCR amplification. Sequence data was 
analysed using Geneious V5.5.7 sequence analysis software and final nucleotide sequences 
were aligned with corresponding reference sequence of the H37Rv reference strain.  
Results 
Of the sixty M.tuberculosis isolates selected, 4 MDR-TB isolates failed to grow sufficiently 
on sub- culture medium and 2 MDR-TB isolates failed numerous attempts at PCR 
amplification. Therefore, we report MIC and sequencing data for 10 SUS, 14 MDR-TB and 
30 XDR-TB M.tuberculosis isolates. 34/54 (81.0%) of the M.tuberculosis isolates included in 
the final analysis were classified as STR resistant. This included all the MDR-TB and XDR-
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TB isolates and 1 DS isolate. All 54 M.tuberculosis isolates were screened for mutations in 
the rrs, rpsL and gidB genes.  
Mutations of the rpsL gene were of 2 types. An A → G substitution on codon 43 (A128G, 
Lys→Arg) and a silent mutation (A→G) on codon 121. The A → G substitution on codon 
43, commonly referred to as the K43R mutation was found in 7/54 (7 MDR-TB) isolates. The 
silent mutation on codon 121 was observed in 30/54 (30 XDR-TB) isolates. Both mutation 
types were associated with an MIC range of 4 to 128 mg/L. No mutations in the rpsL gene 
were observed in any of the drug susceptible isolates tested. 
The gidB mutations were of 5 types: T → G substitution on codon 16 (T47G, Lys→Arg). The 
T → G substitution on codon 16, commonly referred to as the L16R mutation was found in 
35/54 (1 DS, 4 MDR and 30 XDR) isolates. An A → C substitution on codon 92 (GAA-
GAC, Glu→Asp) was found in 13/54 (3 DS and 10 MDR-TB) isolates commonly referred to 
as the E92D mutation. Both these mutations were associated with an MIC range of 0.5 to 128 
mg/L. All 54 isolates displayed an alteration on codon 100 (TCT-TTT, Ser→Phe), 
irrespective of the MIC or resistance profile. This mutation is reffered to as the S100F 
mutation. One DS isolate had a silent mutation on codon 135 (GTG-GTT), associated with an 
MIC of 0.5 mg/L. A 130bp deletion within the gene encompassing codons 50-93 was also 
observed in 34/54 (4 MDR-TB and 30 XDR-TB) isolates tested, associated with an MIC 
range of 4 to 128 mg/L. The 130bp deletion of the gidB gene is shown in figure one. All the 
isolates in this study displayed alteration in the gidB gene. Seven of the STR resistance 
isolates of the MDR phenotype had mutations in the gidB gene only. 
None of the isolates tested displayed any mutations in the rrs gene region linked to STR 
resistance. The relationship between the MIC’s of STR and mutations in the rrs, rpsL and 
gidB genes are shown in Table 3.2. 
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IS6110 genotyping revealed that a majority of drug resistant isolates belonged 
F15/LAM4/KZN (KZN) lineage, whereas the remaining isolates belonged to F28/F11 and 
Beijing strain families. Four isolates used in the study displayed a unique RFLP profile. The 
rpsL K43R mutation was found exclusively in the F28 strain family and the A363G mutation 
was identified in only the KZN XDR-TB strains. The 130bp deletion and L16R mutation in 
the gidB gene were associated with the KZN family. One strain, a variant of the F11 family 
displayed the L16R mutation in the gidB gene. The E92D gidB mutation was identified in all 
strains of Beijing and F28 families, as well as variants of the F28 family. RFLP profiles, 
lineage specific mutations and associated phenotypes are shown in Table 3.3. 
Discussion 
We report on STR resistance in clinical isolates of M.tuberculosis from the KwaZulu-Natal 
province of South Africa in relation to the mutation profiles of the rrs, rpsL, and gidB genes. 
In M. tuberculosis, resistance to STR is associated with alterations within the rrs, rpsL, and 
gidB genes which encode constituents of the 30S ribosomal subunit. Mutations occurring in 
the rpsL and rrs genes have been well characterized, accounting for 70% of STR resistance 
(Da Silva and Palomino, 2011; Spies et al., 2011). Reports on gidB gene mutations remain 
inconsistent, associated with low-level STR resistance and are most predominant in isolates 
with mutations in the rrs or rpsL genes (Jagielski et al., 2014; Okamoto et al., 2007; Verma et 
al., 2014). Furthermore, the relationship between the mutations and the level of STR remains 
unclear (Jagielski et al., 2014; Shi et al., 2007; Verma et al., 2014). 
Numerous studies report that the amino acid substitution on codon 43 (AAG-AGG, 
Lys→Arg) of the rpsL gene is the most common mechanism conferring resistance in STR 
resistant clinical isolates of M.tuberculosis (Da Silva and Palomino, 2011; Dobner et al., 
1997; Fakuda et al., 1999; Honore and Cole, 1994; Jagielski et al., 2014; Verma et al., 2014). 
In our study, this mutation was found in 7 MDR-TB isolates, representing only 18.9% of the 
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rpsL mutations in the STR resistant isolates from this study. This mutation has been 
associated with varying detection rates across geographical areas, ranging between 13.2% 
and 80.4%.   This mutation has been correlated with isolates of the Beijing genotype and with 
isolates of an MDR-TB phenotype (Jagielski et al., 2014; Spies et al., 2011). In our study, this 
mutation was associated with the F28 family, a predominant strain responsible for MDR-TB 
in our setting and in the Western Cape region of South Africa. The A363G silent mutation 
was present in 30 isolates, representing 81.1% of the rpsL mutations in this study. This 
mutation was found exclusively in the XDR-TB isolates, with no additional mutations in 
hotspot regions of the gene. Verma et al. described this mutation in 30/75 STR resistant 
isolates with or without additional alteration on codon 43 or 88 of the rpsL gene (Verma et 
al., 2014). We postulate that this mutation maybe a natural polymorphism, with no link to 
resistance. Furthermore, MDR-TB isolates that did not display the mutation at position 363 of 
the rpsL gene but had a gidB deletion recorded similar MICs to that of the XDR-TB isolates 
with alteration in both the rpsL and gidB genes.  
The gidB gene, a highly conserved gene present in all species sequence to date, is associated 
with low level STR resistance in M.tuberculosis (Verma et al., 2014). In our study, the most 
significant finding was a 130bp deletion within the gidB gene. This mutation does not occur 
with any of the classical rpsL mutations. We believe that this mutation which results in the 
loss of function of the gidB gene, mediates STR resistance in KZN family of strains. Whole 
genome analysis conducted on the KZN family strains by Ioerger et al. described this 
deletion which includes amino acids 50-93, encompassing the SAM binding site and results 
in a frameshift of the C terminal remainder, completely disrupting the function of the gidB 
gene (Ioerger et al., 2009). In our study, this deletion was exclusive to the MDR and XDR-
TB strains of the KZN family. Ioerger et al. detected this mutation in on DS isolate, but 
attributed this finding to mischaracterization of the strain (Ioerger et al., 2009). Whole 
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genome sequencing analysis of strains from Panama, described to be closely related to the 
KZN family of strains, did not display this 130bp deletion. However it was reported that a 
unique 16 bp deletion in the gidB gene was present in both STR resistant and susceptible 
isolates (Lanzas et al., 2013). 
 The L16R and E92D mutations have been described as phylogenetic markers rather than 
resistance mediating mutations. The L16R mutation is specific for the Latin American-
Mediterranean (LAM) family (Spies et al., 2011). Our results are in keeping with these 
reports, as this mutation was present in all 34 KZN isolates. One isolate, a variant of the F11 
family of strains, had this alteration. It is possible that the strain maybe closely related to the 
KZN family as it is classified within the Latin America Mediterranean (LAM 3) lineage. The 
E92D mutation, reported to be specific for the Beijing family was detected in only 3/5 
Beijing isolates in our study. It may be possible that the 2 isolates were misclassified. 
Interestingly, this mutation was detected in all isolates of the F28 family and variants of the 
family. To the best of our knowledge, this mutation has not been reported in the F28 family 
and therefore may not be a representative marker of the Beijing family as previously 
reported. 
The S100T alteration was present in all the isolates tested. It has been described by Verma et 
al. in all 75 isolates analysed in the study, with no link to resistance and is thus a naturally 
occurring polymorphism. Furthermore, protein modelling and MSA mutation mapping of 
codon 100, revealed that substitution was a spontaneous alteration, also identified in the 
H37Rv laboratory strain (Verma et al., 2014).  The G405T silent mutation found in one DS 
isolate did not have any link to resistance.  Analysis of the binding sites on codon 16 revealed 
that this alteration results in a change in binding cavity morphology (Verma et al., 2014). 
This implies that the KZN family of strains with the L16R alteration will naturally display 




Whilst many reports associate the mutations found in the rpsL gene with high-level STR 
resistance  and mutations in rrs gene with low to intermediate resistance level (Cooksey et 
al., 1996; Meier et al., 1996; Tudo et al., 2010), we observed that the mutations on the 
different loci did not discriminate between the levels of STR resistance in the current study. 
The MICs of isolates bearing mutations in the various genes did not differ from each other. 
Jagielski et al. compared the MIC50, MIC90 and median MIC values for STR resistant and 
susceptible isolates to establish a relationship between the mutations and levels of STR 
resistance but found no difference in the MICs amongst isolates (Jagielski et al., 2014). Shi et 
al. analysed 215 clinical isolates using denaturing HPLC analysis to establish if the various 
mutations types could be linked resistance levels but found no close correlation in MICs and 
mutation types (Shi et al., 2007).  
In this study, 4 isolates (8.8%) with MICs in the STR resistant range, did not have any 
mutations that are associated with STR resistance. Three MDR-TB isolates and 1 DS isolate 
had no mutations in the rpsL or gidB genes, while the 3 MDR-TB isolates had only the E92D 
gidB phylogenetic marker. This is in close comparison to other studies that analysed all 3 
genes, ranging from 6.9-22% (Jagielski et al., 2014).  Furthermore, none of the isolates had 
any alteration in the rrs gene related to STR resistance, in keeping with the whole genome 
analysis of KZN strains (Ioerger et al., 2009). Wong et al. reports similar findings. Detection 
of the rrs A1401G mutation was associated with kanamycin resistance and had no bearing on 
STR resistance (Wong et al., 2011). Verma et al. suggests that alteration in the rrs gene at 





Alternate mechanisms such as the role of efflux pumps are believed to mediate resistance in 
the absence of mutations. A report by Spies et al. demonstrated a reduction in the STR MIC 
in the presence of efflux pump inhibitors in STR resistant isolates with mutations in the 
various loci. However, the changes were most significant in isolates that displayed gidB 
mutations. Thus, gidB mutations act in synergy with efflux pumps to confer low level STR 
resistance. Further confirmation is required as well as the identification of novel mechanisms 
that mediate STR resistance (Spies et al., 2008). 
In conclusion, we provide evidence that the main mechanism mediating STR resistance in the 
predominant KZN strain is a rare 130bp deletion within the gidB gene while the classical 
K43R mutation of the rpsL gene is linked to resistance in the F28 MDR-TB strain. The low 
detection rate of the rpsL and rrs mutation in this subset of isolates questions the utility of 
these mutations as accurate predictors of STR resistance. Whilst previous findings suggest 
the role of gidB gene mutations as phylogenetic markers, results of this study show that the 
E92D mutation was not exclusive to the Beijing lineage. Furthermore, none of the resistance 
conferring mutations detected in this study could predict the level of STR resistance. Our 
results suggest that STR should not be applied to empiric TB treatment regimens and should 
not be applied to tailored regimens in the absence of drug susceptibility testing. 
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Table 3.1: Oligonucleotide Primers used for PCR & Sequencing 





rpsL rpsL F GGCCGACAAACAGAACGT 502 (Sreevatsan et 
al., 1996) rpsL R GTTCACCAACTGGGTGGAC 
Rrs rrs F TGCTTAACACATGCAAGTCG 920 (Jugheli et al., 
2009) rrs R TCTCTAGACGCGTCCTGTGC 
gidB gidB F GTCCCTCCACTCGCCATC 675  (Spies et al., 














Table 3.2: Relationship between the STR MIC, RFLP analysis and mutations in the rpsL, rrs 










Rrs rpsL gidB 
DS 2 Beijing 
2 Unique 
None None S100F only 4 0.5 
DS Beijing None None S100F only 1 4 
DS F11V None None L16R + S100F  1 0.5 
DS Unique None None S100F + G405T 1 0.5 
DS Beijing None None E92D + S100F 3 0.5 
MDR F28 
F28V 
None None E92D + S100F 2 4 
MDR F28 None None E92D + S100F 1 8 
MDR KZN None None L16R + S100F + 
130 bp Deletion 
1 32 
MDR KZN None None L16R + S100F + 
130 bp Deletion 
3 128 
MDR F28 None K43R E92D + S100F 6 4 
MDR F28 None K43R E92D + S100F 1 128 
XDR KZN None A363G L16R + S100F + 
130 bp Deletion 
10 4 
XDR KZN None A363G L16R + S100F + 








Figure one depicts the 130bp deletion of the gidB gene which includes codons 50-93, 
encompassing the SAM binding site and results in a frameshift of the C terminal remainder, 
completely disrupting the function of the gidB gene. The first 3 chromatograms respresent the 
F15/LAM4/KZN XDR strains, the fourth represents an MDR strain of the same strain family 










Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of 
Mycobacterium tuberculosis. 
Published in the Journal of Infection and Drug Resistance: 
Dookie N, Sturm AW, Moodley P. Moxifloxacin resistance in the F15 / LAM4 / KZN 
extensively drug-resistant strain of Mycobacterium. Infect Drug Resist 2014; 7: 223–8. 
Abstract 
Objectives: Moxifloxacin (MXF) has been advocated for the treatment of extensively drug-
resistant (XDR) tuberculosis despite resistance to older-generation fluoroquinolones. We 
investigated the relationship between the minimum inhibitory concentration (MIC) of MXF 
and mutations in the gyrA and gyrB genes in Mycobacterium tuberculosis (MTB) isolates 
from KwaZulu-Natal (KZN) Province of South Africa. 
Materials and methods: MICs of 56 MTB isolates were compared to the mutations in the 
quinolone resistance-determining region known to confer fluoroquinolone resistance. Isolates 
were genotyped by IS6110 restriction fragment length polymorphism analysis. 
Results: The circulating F15/LAM4/KZN XDR strain circulating in KZN Province harbored 
the A90V mutation and displayed high-level resistance with MICs of 8 mg/L for 
ciprofloxacin and ofloxacin and ≥1 mg/L for MXF. 
Conclusion: The inclusion of MXF in XDR-TB treatment regimens requires careful 
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Introduction 
The human immunodeficiency virus (HIV) pandemic has fuelled the tuberculosis (TB) 
epidemic by creating a population of immunosuppressed individuals that are highly 
susceptible to Mycobacterium tuberculosis (MTB) infection. The last decade has seen an 
unprecedented increase in antimycobacterial drug resistance. Of the estimated 1.3 million 
deaths resulting from TB globally in 2012, 13.1% of these deaths were due to drug 
resistance. Appropriate treatment of patients with drug-resistant strains of MTB is of vital 
importance in limiting the transmission of the disease and reducing mortality rates.1 
Fluoroquinolones are potent antibiotics that have been used in clinical practice since the early 
1980s.2 They display broad-spectrum antimicrobial activity, and have been used extensively 
in the treatment of bacterial infections of the respiratory, gastrointestinal, and urinary tracts, 
as well as in sexually transmitted diseases and chronic osteomyelitis.3 The fluoroquinolones 
have been advocated for the treatment of patients with multidrug-resistant (MDR) MTB, 
defined as resistance to at least isoniazid and rifampicin. Patients with extensively drug-
resistant (XDR) MTB harbor MDR TB strains with additional resistance to fluoroquinolones 
and one of the second-line antimycobacterial injectable (kanamycin, amikacin, and 
capreomycin) agents. However, moxifloxacin (MXF), a new-generation fluoroquinolone, has 
been recommended by the World Health Organization (WHO) for the treatment of XDR. 
Studies that have explored the efficacy of MXF against XDR strains of MTB have concluded 
that the drug may be used in XDR cases provided that the infecting isolate has a minimum 
inhibitory concentration (MIC) of <2 mg/L for MXF.1,4 
MXF differs in structure when compared to ofloxacin (OFX) and ciprofloxacin (CPX). The 
structural difference, which includes a methoxy group in the C-8 position of MXF, results in 
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increased bactericidal activity of the drug, lower MICs, and a lower propensity for the 
development of resistance to the drug.5 Although cross-resistance has been reported, it has 
been argued that the increased bactericidal activity of MXF and the lower MIC allow for this 
drug to be effective against XDR isolates where CPX and OFX are ineffective.3,4 
The fluoroquinolones inactivate the deoxyribonucleic acid (DNA) gyrase enzyme, thereby 
preventing transcription during cell replication. DNA gyrases are encoded by the gyrA and 
gyrB genes. Fluoroquinolone-resistant strains of MTB most frequently display mutations on 
codons 90, 91, and 94 of the gyrA gene.6–9 Additionally, double mutations in the gyrA or 
concomitant gyrA and gyrB mutations have been reported.6,8 The level of fluoroquinolone 
resistance is dependent on the mutation in the resistance-conferring gene and the 
fluoroquinolone tested.10 Studies have demonstrated that MIC levels of resistant isolates are 
higher for older-generation fluoroquinolones than for MXF.6–9 
The use of MXF in XDR treatment regimens was introduced without prior testing for 
susceptibility against the circulating XDR isolates in KwaZulu-Natal (KZN) Province. The 
aim of this study was to correlate the minimum inhibitory concentration (MIC) levels of the 
fluoroquinolones with mutations in the gyrA and gyrB genes in a subset of clinical isolates 
from the KZN Province of South Africa. 
Materials and methods 
Clinical isolates 
The isolates used in this study were retrieved from the culture collection in the Department of 
Infection Prevention and Control, Nelson R Mandela School of Medicine, School of 
Laboratory Medicine and Medical Science, College of Health Science, University of 
KwaZulu-Natal. We included the following phenotypes: ten fully drug-susceptible (DS), 20 
MDR, and 30 XDR. The isolates were collected between 2005 and 2008 from patients in 
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Umzinyathi District, KZN, South Africa. H37Rv was included as the reference strain. Ethical 
approval for the study (BREC 247/09) was granted by the Biomedical Research Ethics 
Committee at the University of KwaZulu-Natal. 
MIC determination 
MIC determination of the drugs was performed by means of the agar dilution method using 
Middlebrook 7H10 (BD, Franklin Lakes, NJ, USA) media supplemented with oleic acid–
albumin–dextrose–catalase (BD). The drug concentrations used ranged from 0.03 to 8 mg/L 
for CPX, OFX (Sigma-Aldrich, St Louis, MO, USA), and MXF (Bayer, Leverkusen, 
Germany). Following inoculation, plates were incubated in a CO2 (5%)-enriched atmosphere 
at 37°C for 21 days. MIC values were recorded as the lowest concentration of the drug that 
resulted in complete inhibition of growth. The cutoff value for resistance ≥2 mg/L for CPX 
and OFX according to WHO recommendations and ≥0.5 mg/L for MXF, as described by 
Angeby et al.11,12 All MIC experiments were carried out in triplicate. 
DNA extraction and PCR 
DNA was extracted using cetyl-trimethyl-ammonium bromide-sodium chloride, as 
previously described.13 The quinolone resistance-determining region (QRDR) and flanking 
regions of the gyrA and gyrB genes were amplified using primer pairs designed for this study: 
gyrA forward (CGATTGCAAACGAGGAATAG), gyrA reverse 
(GGCCAGTTTTGTAGGCATCA), and gyrB forward (ATCAACCTGACCGACGAGAG), 
gyrB reverse (GCCGAGTCACCTTCTACGAC).14 Polymerase chain reaction (PCR) was 
performed using the Expand high-fidelity PCR system (dNTPack; Hoffman-La Roche, Basel, 
Switzerland). 
Cycling conditions were as follows: initial denaturation at 94°C for 2 minutes; 40 cycles of 
denaturation at 94°C for 45 seconds, annealing at 53°C (gyrA) or 56°C (gyrB) for 45 seconds 
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and extension at 72°C for 45 seconds; and a final extension of 7 minutes at 72°C. The quality 
of PCR amplicons was checked on a 1% agarose gel. 
Sequencing PCR products were purified using the Invitrogen PureLink® PCR purification kit 
(Thermo Fisher Scientific, Waltham, MA, USA). The sequencing reactions were performed 
using an ABI Prism BigDye® Terminator cycle-sequencing kit 3.1 (Thermo Fisher 
Scientific) with the same forward primers as used for PCR amplification. Geneious version 
5.5.7 sequence-analysis software was used to identify mutations in the final nucleotide 
sequences in comparison to the MTB H37Rv reference strain.15 
Genotyping 
Genotyping was performed by IS6110 restriction fragment length polymorphism (RFLP) 
analysis using the Southern blot hybridization method, as previously described.16 
Results 
Isolates 
Of the 60 isolates selected, four MDR isolates did not grow sufficiently on retrieval 
subculture and were excluded from further analysis. MIC and sequencing data were therefore 
obtained for ten DS, 16 MDR, and 30 XDR isolates. 
MIC results 
The DS and MDR isolates displayed MICs for CPX, OFX, and MXF in the susceptible 
range. All 30 XDR isolates tested displayed MICs for CPX, OFX, and MXF that were in the 
resistant range (Table 4.1). 
Sequencing of the gyrA and gyrB genes 
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Three mutations were observed in the nucleotide sequence of the gyrA gene: E21Q 
(GAA→CAA), S95T (ACG→ACC), and A90V (GCG→GTG). E21Q and S95T were 
present in all 56 isolates, regardless of MIC values (Table 1). The A90V mutation was 
present only in the 30 XDR isolates, correlating with an MIC value of 8 mg/L for CPX and 
OFX. In the case of MXF, 23 of the 30 XDR isolates had an MIC value of 2 mg/L, while 
seven had an MIC value of 1 mg/L. Ten MDR isolates with an MIC for MXF at the proposed 
breakpoint for resistance, ie, 0.5 mg/L, did not display the A90V mutation. No mutations 
were detected in the gyrB genes of the isolates tested. 
IS6110 restriction fragment length polymorphism analysis 
IS6110 RFLP analysis revealed that 35 of the 56 isolates belonged to the F15/LAM4/KZN 
family of strains. This included all 30 XDR isolates and five MDR isolates. Seventeen of the 
remaining isolates belonged to recognized strain families (F28, F11, and Beijing) while four 
showed a unique RFLP profile. 
Discussion 
We report on the correlation between MICs of MXF and mutations in the gyrA gene in a 
selection of clinical isolates in KZN, South Africa. Fluoroquinolone resistance in MTB is 
most frequently attributed to mutations occurring in the QRDR of the gyrA gene. The QRDR 
of the gyrA gene consists of a short region, coding for amino acids 74–113. In our study, we 
sequenced the QRDR of both the gyrA and gyrB genes, as well as flanking regions. We found 
the C269T mutation within the QRDR of the gyrA gene, which corresponds with the amino 
acid change A90V, correlated with the high MICs seen in the XDR MTB isolates that we 
studied. The A90V mutation in gyrA has been described as one of the most frequent 
mutations associated with fluoroquinolone resistance.17 In our study, based on WHO-
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recommended breakpoints, the A90V mutation in XDR isolates was linked to resistance in all 
three fluoroquinolones tested.11 
We did not find mutations in gyrB in any of the isolates tested. This supports previous 
observations that mutations within the gyrB gene are rare in MTB.8,17 Maruri et al conducted 
a systematic review to evaluate gyrase mutations associated with fluoroquinolone resistance 
in MTB. The study reported on 534 fluoroquinolone-resistant MTB isolates, of which 17 
(3%) harbored mutations within the QRDR of the gyrB gene. In addition, four different 
numbering systems were used to report on mutations in the gyrB gene, resulting in major 
discrepancies. The authors proposed a uniform numbering system in an attempt to improve 
the molecular detection in the gyrases.18 The significance of mutations within the QRDR of 
the gyrB gene cannot be ignored, and is thought to play an important role in resistance.9 
WHO guidelines propose 0.5 mg/L as the breakpoint MIC for susceptibility testing of MXF 
in the BACTEC™ 460 system (BD) and 0.25 mg/L in the BACTEC MGIT 960 (BD) 
system.11 Breakpoints for other test systems are not proposed. Angeby et al demonstrated 
comparable MIC results for MXF on Middlebook 7H10 agar and the BACTEC 460 system.12 
With Middlebrook 7H10 plates used for MIC determination, all our XDR isolates had MICs 
of >0.5 mg/L. As per the WHO definition, these are classified as MXF-resistant, and this 
implies that MXF should not be recommended for treatment of cases harboring such isolates. 
However, there are reports of MXF efficacy in isolates with MXF MICs <2 mg/L.3,4,6,10,19 
Poissy et al used the murine model to demonstrate that MXF is effective against OFX-
resistant strains. They reported that MXF was most effective on MTB strains with MICs ≥0.5 
mg/L. Reduced mortality was observed in mice infected with strains, with MICs ≥2 mg/L 
compared to untreated controls.4 Fillion et al demonstrated similar findings using the murine 
model to determine the effect of a multidrug regimen containing MXF. The sterilizing 
92 
 
activity of the multidrug regimen decreased in strains with increased MICs to MXF. The 
impact of the sterilizing activity of the most effective second-line treatment regimen (ie, 
ethionamide, pyrazinamide, amikacin, and MXF) is dependent on the MIC of MXF, and thus 
the MIC of MXF has to be determined for all strains resistant to OFX. Mice infected with 
strains with MXF MICs of 0.5 mg/L and 4 mg/L recorded relapse rates of 50% and 86%, 
respectively, compared to the wild type.10 
Sirgel et al proposed that MXF and OFX are possibly not equally affected by mutations 
associated with fluoroquinolone resistance.6 They concluded that the use of MXF for the 
treatment of infection with OFX-resistant strains is justified when combined with other 
drugs. They further suggested that the low recommended breakpoint of 0.5 mg/L determining 
MXF resistance may therefore give a false impression of clinical inactivity. Poissy et al and 
Sirgel et al support WHO recommendations on the use of MXF for the treatment of XDR 
provided that the infecting isolate has an MXF MIC of <2 mg/L.4,6 
Feasey et al reported on a case where high-dose MXF (600 mg/day) in combination with 
PZA, CAP, LIN, PAS, and amoxicillin clavulanic acid for 22 months successfully treated a 
case with an infecting isolate that was resistant to isoniazid, rifampicin, ethambutol, 
prothionamide, OFX, streptomycin, and MXF (MIC of 2 mg/L). While high-dose MXF 
treatment increases the peak plasma (MXF), resulting in levels that remain constantly above 
the MIC, it is difficult to assess the exact role of MXF in the successful management of this 
patient, since other drugs with known efficacy were also included in the treatment regimen.19 
Jacobson et al conducted a meta-analysis to assess treatment outcomes in patients with XDR. 
The report summarized 13 studies conducted mainly amongst HIV-uninfected people, who 
received a new-generation fluoroquinolone together with other anti-TB drugs. They 
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concluded that the addition of MXF to XDR regimens may improve outcomes, but further 
evaluation in clinical trials is warranted.3 
In KZN, the regimen used for XDR treatment is a combination of drugs with proven and 
putative efficacy. The National Department of Health in South Africa recommends the use of 
MXF as part of XDR treatment in the presence of OFX resistance. Fluoroquinolones are 
added despite in vitro reports of resistance in the hope that there may be some residual 
activity. It is debatable whether the perceived benefit of using MXF under these 
circumstances outweighs the risks caused by side effects of this drug or the increased 
exertion of antibiotic pressure in the era of ever-increasing drug resistance.20 Mendel and 
Springsklee21 warned that the use of newer-generation fluoroquinolones in patients that 
display low-level resistance will be disastrous from a public health perspective. The use of 
MXF in such cases will result in the ready emergence of highly resistant strains unless drug 
concentrations are sustained above mutant-prevention concentrations at all infection sites. 
The latter is extremely difficult to achieve, and thus the use of MXF in patients with 
resistance to older-generation fluoroquinolones will only further drive resistance among 
XDR strains of MTB. 
Although all isolates used in this study were from different patients, the XDR isolates 
displayed a high degree of similarity and belonged to a single genotype, ie, F15/LAM4/KZN. 
To date, all reports from KZN have attributed XDR to this strain. Ramtahal showed that the 
spread of XDR in KZN was clonal with the F15/LAM4/KZN strain.22 Clonal spread of this 
strain has been ongoing since at least 2005.23 During this period, further acquisition of 
resistance may have occurred. We therefore performed susceptibility testing and sequencing 
on 30 XDR isolates belonging to the only XDR strain family currently in KZN. Seven of the 
isolates had MICs of 1 mg/L, and 23 had MICs of 2 mg/L. Basic microbiological principles 
regarding in vitro determination of MICs allows for one twofold MIC variation between 
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tests. This implies that our XDR isolates may in their most susceptible form have MICs 
between 0.5 and 1 mg/L and in their most resistant form from 2 to 4 mg/L.24 Gandhi et al 
found that a large variety of strains were associated with DS, and this decreased as the degree 
of resistance increased. The low diversity of strains driving the MDR and XDR epidemics 
supports the theory of clonal expansion of drug-resistant phenotypes in KZN. This picture is 
different in other parts of South Africa. In the Eastern and Western Cape Provinces, the 
Beijing strain is accountable for the majority of XDR. Strains responsible for MDR and XDR 
in other provinces include the S, T1, and other families. The reasons for geographic 
differences remain uncertain.25 
Conclusion 
Regardless of the strain family implicated in infection with XDR, the breakpoint for 
resistance to MXF remains the subject of debate. Our results support concerns regarding the 
use of MXF in KZN. While there may be a role for MXF as part of individualized XDR 
treatment regimens, this cannot be advocated as part of empiric treatment protocols in the 
absence of MXF MIC data of the circulating XDR strains in an area. In addition, validation 
from larger population-based studies using MXF in combination with various other antidrug 
regimes must be conducted. Early bactericidal assays with MXF will also give useful data to 
inform our practice. 
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Table 4.1 RFLP strain families of Mycobacterium tuberculosis isolates stratified by MIC and 
resistance conferring mutations in the gyrA gene 






CPX OFX MXF 








































LAM3/F11 1 (DS) None 0.5 0.5 0.125 
Beijing family 6 (DS) None 0.5 0.5 0.125 










Note: aResistance defined as 2 mg/L for CPX and OFX and 0.5 mg/L for MXF. 
Abbreviations: RFLP, restriction fragment length polymorphism; MIC, minimum inhibitory 
concentration; CPX, ciprofloxacin; OFX, ofloxacin; MXF, moxifloxacin; XDR, extensively 





Evaluation of Capreomycin in the treatment of the F15/LAM4/KZN extensively drug-
resistant strain of Mycobacterium tuberculosis. 
Currently under review by the Journal of Chemotherapy (Manuscript number: JOC 
745) 
Abstract: 
 Capreomycin has been advocated for the treatment of extensively drug resistant tuberculosis 
without drug susceptibility testing.  We investigated the relationship between the minimum 
inhibitory concentration of CAP and mutations in the rrs, tlyA and eis genes in 
Mycobacterium tuberculosis isolates from KwaZulu-Natal, South Africa. MIC data of 56 
isolates were compared to mutations in the rrs, tlyA and eis genes. Mutational analysis 
identified the A1401G mutation in the rrs gene in 30 XDR-TB isolates with an MIC of ≥ 16 
mg/L for CAP and ≥ 128 mg/L for kanamycin and amikacin. Genotypic analysis revealed 
that the XDR-TB strains were clonal belonging to the F15/LAM4/KZN strain family. The 
MICs of CAP reveal that the use of the drug in XDR-TB treatment protocols requires careful 
re-consideration in the KZN setting. A review of the current breakpoint value for CAP will 
be invaluable in improving the quality of drug susceptibility testing against MTB. 
Introduction 
In 2013, 9.0 million new cases of tuberculosis (TB) and 1.5 million TB-related deaths were 
reported worldwide. While the global incidence of TB has decreased, multidrug-resistant 
(MDR-TB) and extensively drug resistant (XDR-TB) remain a major public health concern 
in several countries. MDR-TB, as defined by World Health Organisation (WHO), are 
Mycobacterium tuberculosis (MTB) strains that are resistant to isoniazid (INH) and 
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rifampicin (RIF). XDR-TB strains are characterized by resistance to INH and RIF (ie MDR-
TB) with additional resistance to a fluoroquinolone and one of the three injectable agents: 
amikacin (AMIK), kanamycin (KAN) and capreomycin (CAP).1  
The treatment of XDR-TB is a major challenge given the paucity of effective drugs available. 
Antimicrobial regimens that are currently used to treat XDR-TB, often do not take cross 
resistance among drug classes into consideration. In addition, inclusion of anti-TB drugs into 
the XDR-TB treatment protocols are often advocated without appropriate drug susceptibility 
testing (DST) of locally prevalent XDR-TB strains.  
In 2006, a report by Gandhi et al.2 underscored the drug resistance TB problem in which the 
largest ever outbreak of XDR-TB was described in Tugela Ferry, KwaZulu-Natal, South 
Africa. The isolates from TB cases described in this outbreak were resistant to INH, RIF, 
KAN, and ofloxacin (OFX). 2 This prompted the Department of Health in South Africa to 
look at alternatives for the treatment of patients with XDR-TB. It was recommended that two 
drugs that were previously used to treat TB, be reintroduced for the management of XDR-TB 
cases.3 
 The drugs recommended were CAP (a polypeptide with a similar mode of action to 
aminoglycosides) and para-amino salicylic acid (PAS). The Medicines Control Council 
(MCC) registration for the latter was still in effect. However, MCC registration for CAP had 
expired, and a new approval was sought and granted. It was presumed that strains of XDR-
TB would be susceptible to CAP and PAS, and susceptibility testing for these drugs against 
XDR-TB strains was therefore not performed at the outset. 3 
The treatment of MDR-TB in South Africa includes an aminoglycoside i.e. KAN or AMIK. 
With the emergence of XDR-TB strains in KZN, CAP became an integral part of treatment 
regimens amid extensive aminoglycoside resistance. 4 The aminoglycosides (KAN and 
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AMIK) and cyclic polypeptides (CAP) are protein synthesis inhibitors that act by binding to 
the bacterial ribosome resulting in a modification of the 16S rRNA structure.5 Resistance to 
all three of these antibiotics have b4een linked to mutations in the rrs gene coding for 16S 
rRNA and the tlyA gene which encodes an rRNA 2’ –O-methyltransferase responsible for 
methylation of nucleotide C1409 in helix 44 of the 16S rRNA. In addition, cross resistance 
amongst these agents has been reported.6-9  Recent reports have demonstrated that mutations 
in the eis promoter, a putative enhanced intracellular survival protein in M.Smegmatis, is 
linked to KAN resistance. 5, 9, 10 
Rapid molecular diagnostic assays used to identify drug resistance in clinical isolates rely on 
the identification of mutations in known resistance conferring genes. Whilst this phenomenon 
is well established for first line agents, molecular based testing for resistance to second line 
agents has not been well characterized. A greater understanding of these mechanisms is 
imperative to appropriately guide treatment in patients with MDR-TB and XDR-TB. 5, 6, 8 
The aim of this study was to correlate the Minimum Inhibitory Concentration (MIC) levels of 
the aminoglycosides and CAP with mutations in the genes known to confer drug resistance in 
a subset of clinical isolates from the KZN province of South Africa. 
Materials and Methods 
Clinical Isolates 
A total of 60 isolates were included in this study: 10 drug susceptible (DS), 20 MDR and 30 
XDR. The isolates were collected during 2005-2008 from in and out patients at the Church of 
Scotland Hospital, Tugela Ferry, KZN, South Africa. H37Rv was included as the reference 
strain. Ethical approval for the study (BREC 247/09) was granted by the Biomedical 





We established the MIC on Middlebrook 7H10 agar (BD, Difco Laboratories, USA) medium 
supplemented with oleic acid-albumin-dextrose-catalase (OADC) (BD, Difco Laboratories, 
USA) using the agar dilution method. Bacterial cultures were prepared by adjusting the 
bacterial suspension to give a turbidity equivalent to that of a 1.0 McFarland standard and 
then diluted to obtain a final bacterial density of 1 x 10-3 colony forming units per ml. 0.1ml 
was used to inoculate each quadrant of the Middlebrook 7H10 agar plates with dilutions 
ranging from 0.06 – 16 mg/L for CAP and 0.5 – 128 mg/L for KAN and AMIK. All drugs 
were obtained from Sigma-Aldrich (Capital Lab Supplies, South Africa). Plates were 
incubated in a CO2 enriched atmosphere at 37ºC for 21 days.  The MIC was defined as the 
lowest antibiotic concentration that resulted in a complete inhibition of growth. Resistance 
was determined at a critical concentration of 5 mg/L for KAN, 4 mg/L for AMIK and 
10mg/L for CAP. 11  All experiments were carried out in triplicate to ensure accuracy and 
reproducibility.  
Gene Amplification and Sequencing 
Genomic DNA was isolated using the CTAB-NaCl (Cetyl-trimethyl-ammonium Bromide-
Sodium Chloride) as described previously. 12 
PCR amplification of all 56 isolates for the rrs gene was performed using the Expand High 
Fidelity PCR system, dNTPack (Roche Diagnostics, Mannheim, Germany) and primers KM-
SA, KM-RA, P1 and P2 and cycling protocol as described previously. 6 The tlyA gene was 
amplified using newly designed primers: tlyAF (AAGGCATCGCACGTCGTCTTTCC) and 
tlyAR (TGTCGCCCAATACTTTTTCTACGC). The eis gene was amplified using primers 
AZ80 and AZ87.7 The cycling protocol utilised was an initial denaturation at 94ºC for 2 mins 
followed by 40 cycles of denaturation at 94ºC, annealing at 60ºC (tlyA) and 58 ºC (eis); 
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extension at 72ºC for 45secs each and a final extension of 10 min at 72ºC. The quality of 
PCR products were checked on a 1% agarose gel purified using the Invitrogen PureLink PCR 
purification kit (Applied Biosystems, South Africa), matching 831bp and 920bp for the 2 
regions of the rrs gene. The tlyA gene yielded a 981bp product and the eis gene 567 bp 
product.  
Direct single stranded sequencing of the rrs and tlyA amplicons was performed using ABI 
Prism Big Dye Terminator cycle sequencing kit V3.1 (Applied Biosystems, South Africa) 
with the forward primers used for PCR amplification. Geneious V5.5.7 13 sequence analysis 
software was used to detect mutations in the final nucleotide sequences in comparison to the 
H37Rv reference strain.  
RFLP Analysis 
Isolates were genotyped using the IS6110 restriction fragment length polymorphism (RFLP) 
method as described previously. 14 The Bionumerics version 3.5 software (Applied Maths, 
Kortijk, Belgium), was used for the analysis of IS6110 RFLP patterns. 
Results 
Of the sixty isolates selected for analysis, 4 MDR-TB isolates failed to grow sufficiently on 
sub- culture and had to be excluded. Therefore, we report MIC and sequencing data for 10 
SUS, 16 MDR-TB and 30 XDR-TB isolates. 
MIC Results 
The 30 XDR-TB isolates were found to be resistant to KAN, AMIK and CAP with MIC’s of 
> 128mg/L for KAN and AMIK and ≥ 16 mg/ L for CAP. The isolates classified as SUS and 
MDR-TB displayed MICs for KAN, AMIK and CAP in the susceptible range. The MIC 
profiles for KAN, AMIK and CAP are shown in Table 5.1. 
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Sequencing of the of the rrs and tlyA genes 
Sequencing of the 56 isolates revealed 2 mutations: The rrs A1401G and the tlyA A33G.  The 
rrs A1401G mutation was found in all 30 XDR-TB isolates, correlating with MIC values 
>128 µg/ml for KAN and AMIK and ≥16µg/ml for capreomycin. The SUS and MDR-TB 
isolates did not display any mutations in this gene. The tlyA A33G mutation was present in 
all 56 isolates, regardless of MIC values. No mutations were detected in the eis genes in the 
isolates tested. Sequencing results are shown in Table 5.2. 
RFLP Genotyping Results 
RFLP analysis revealed that the majority of the isolates belonged to the F15/LAM4/KZN 
lineage, whereas the remaining isolates belonged to recognised strain families (F28/F11 and 
Beijing). Four isolates used in the study displayed a unique RFLP profile. The A33G tlyA 
mutation was found in all isolates whilst the A1401G rrs mutation was found only in the 
F15/LAM4/KZN lineage. RFLP profiles, mutations and associated phenotypes are shown in 
Table 5.2. 
Discussion 
In this study, we report on the association between MICs of CAP and the aminoglycoside 
antibiotics and mutations in the rrs, tlyA and eis genes in clinical isolates of MTB from our 
setting. Resistance to the injectable antibiotics are commonly associated with the A1401G 
mutation in the rrs gene. 5-9 In our study, sequencing revealed the A1401G mutation in the rrs 
gene correlated with high level resistance in the F15/LAM4/KZN XDR-TB strains. The five 
F15/LAM4/KZN MDR-TB strains susceptible to CAP did not carry the rrs A1401G 
mutation.  It has been reported that the A1401G rrs mutation alone detected approximately 
70-80% of CAP and AMIK resistance and 60% of KAN resistance, globally. 9 Our findings 
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show that the A1401G mutation in XDR-TB isolates confers high level resistance to KAN 
and AMIK and a decreased susceptibility to CAP, corroborating previous reports. 5, 6, 8, 9 
Mutations in the tlyA gene have been implicated in CAP resistance. Sequencing of the tlyA 
gene revealed the A33G mutation in all the isolates tested. Sowajassatakul et al.15 recently 
reported that the tlyA A33G substitution does not result in any amino acid changes, 
suggesting that this mutation is merely a natural polymorphism with no link to the resistant 
phenotype. 15 The results of this study corroborates this finding. Although mutations 
conferring resistance in the tlyA gene have been reported in only 1-3% of CAP resistant 
strains, there are no reports of these mutations in CAP sensitive strains therefore, the 
significance of tlyA mutations should not be ignored as they have potential to serve as high 
predictor of CAP resistance.9 
 Mutations in the promoter region of the eis gene, coding for an aminoglycoside 
acetyltransferase, are associated with low-level KAN resistance.9 In our study, no mutations 
were detected in any of the isolates studied. Common mutations associated with resistance 
occur at positions -10, -14 and -37. eis promoter mutations are reported to  occur exclusively 
in KAN resistant isolates with no additional mutation in rrs gene, therefore, they have a 
greater predictive potential for detecting KAN resistance than using the A1401G rrs mutation 
alone. 9, 10 
The emergence of MDR-TB and XDR-TB has created a higher demand for antimicrobial 
DST. Current DST against M.tuberculosis is based on the testing of an antimicrobial against 
a set concentration known as the breakpoint concentration; defined as the lowest 
concentration of drug that will inhibit 95% (90% for pyrazinamide) of wild-type strains that 
have never been exposed to the drug, while not inhibiting clinical strains that display 
resistance to the drug. Angeby et al.16 considers this definition to be flawed as it categorises 
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5% of the wild-type strains to be resistant. In addition, combination therapy is mandatory for 
the treatment of M.tuberculosis and therefore clinical outcome data for individual drugs are 
not readily available. They propose the use of wild-type MIC distributions for indicating 
susceptibility breakpoints for M.tuberculosis. The highest MIC value within the wild-type 
MIC range is defined as the epidemiologic cut-off value (ECOFF), is considered a more 
accurate tool for indicating susceptibility breakpoints for M.tuberculosis. 16 The tentative 
ECOFF value for CAP is 4 mg/L whilst current WHO guidelines on DST recommend a 
breakpoint concentration of 10 mg/L for CAP on Middlebrook agar. 11,16 By applying the 
ECOFF value of 4mg/L for CAP, all  SUS and MDR-TB isolates used in our study with 
MICs of 4mg/L display low-level resistance to CAP. Reeves et al.17 reported on the 
disparities associated with the rrs A1401G mutation. They conducted MIC’s in clinical 
isolates and genetically engineered mutants that had clean genetic backgrounds and no prior 
exposure to the drug. The MIC’s for the clinical isolates ranged from 8 mg/L to 40 mg/L. All 
the genetically engineered mutants had an MIC of 40 mg/L. They suggest a re-evaluation of 
the current breakpoint value for CAP and that the differences in resistance levels are due to 
compensatory or second site mutations.17 
CAP resistance was reported in the F15/LAM4/KZN strain prior to the use of the antibiotic in 
South Africa.18 This phenomenon was also reported by Sirgel et al. 8 in the Eastern Cape 
region of South Africa and Jugheli et al. 6 in isolates from Georgia. This suggests that CAP 
resistance occurs as a result of cross resistance to KAN and AMIK and that the drug 
therefore has no clinical relevance in treatment regimens for XDR-TB. 6,8 
Sirgel et al. 8 suggests that CAP MIC’s in the range of 10-15 mg/L warrants the clinical use 
of CAP in treatment of patients infected with strains resistant to low level CAP based on the 
fact that it is below achievable serum levels. 11 In our subset of isolates, all XDR-TB isolates 
displayed MIC’s of ≥16 mg/L. This MIC could in fact be much higher as basic 
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microbiological principles for in vitro MIC determination allows for one twofold variation of 
the real end point. Thus, our XDR-TB isolates could in their most resistant form have MIC’s 
of 32-64 mg/L which exceed the peak serum concentrations levels of 20-47 mg/L for CAP. 
Therefore, the concentration of the drug will be inadequate for patient’s harbouring strains 
resistant to CAP. Furthermore, we believe that the use of CAP in the treatment of patients 
with low-level CAP resistance will only drive further resistance in these isolates.   
Although all isolates used in this study were from different patients, the XDR-TB isolates 
belonged to the F15/LAM4/KZN genotype. Thus far, all reports of XDR-TB in the KZN 
province of South Africa have been attributed to this genotype. 19 The strains analysed in this 
study are highly resistant, presenting clinicians with few therapeutic options. The 
aminoglycosides, CAP and the fluoroquinolones remain the most effective agents in the 
treatment of drug-resistant strains of MTB.  The present study has, consequently, important 
implications for the treatment of XDR-TB in South Africa. The re-introduction of CAP in 
drug regimens for treatment in patients with resistance to KAN or AMIK in the absence of 
drug susceptibility testing possibly amplified this drug resistance. We suggest that the current 
breakpoint concentration set out for CAP needs to be revised in order to prevent patients 
from receiving inadequate treatment that could lead to the development of further resistance, 
continued transmission of drug resistant strains as well as death of the patient. However, this 
can only be determined if CAP is assessed in combination with suitable companion drugs, 
which may not be available.  Therefore, the clinical use of CAP needs careful re-
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Table 5.1: MIC profiles for KAN, AMIK and CAP in 56 isolates from patients from 
KwaZulu-Natal, South Africa 
No of Isolates MIC  (mg/L) 
KAN AMIK CAP 
30 (XDR-TB) >128 >128 >16 
1 (MDR-TB) 4 2 8 
5 (1 SUS, 4 MDR-
TB) 
4 2 4 
11(5 SUS, 6 
MDR-TB) 
2 2 4 
9 (4 SUS, 5 MDR-
TB) 












Table 5.2: RFLP analysis of M. tuberculosis isolates with mutations and their associated 
phenotypes 
 
Strain Family Mutations No of Isolates 









F28 None A33G None 10 (MDR) 
LAM3/ F11 None A33G None 1 (SUS) 


























KZN Multidrug and Extensively drug resistant strains of Mycobacterium tuberculosis 
remain susceptible to Linezolid and para-Amino salicylic Acid. 
Submitted to the South African Medical Journal 
Abstract 
Background: Strategic application of Linezolid (LIN) and para-Amino salicylic acid (PAS) 
may play an important role in the management of drug resistant tuberculosis in our setting.  
Objectives: The aim of this study was to screen clinical isolates of M.tuberculosis for 
resistance LIN and PAS. 
Methods: In an attempt to detect resistance to LIN and PAS, we screened the rrl and thyA 
genes of drug susceptible, multi drug-resistant (MDR) and extensively drug-resistant (XDR) 
clinical isolates of Mycobacterium tuberculosis. 
Results: No resistance mutations were detected in the thyA and rrl genes in the isolates 
screened. The presence of the Thr202Ala mutation in thyA and the G2399A mutation in the 
rrl gene was associated with strains of Latin American Lineage and played no role in 
mediating resistance to the drugs.  
Conclusions: Failure to associate LIN or PAS resistance to the most common mechanisms 
described underscores the need for more effective screening of novel targets and detection of 
resistance mechanisms that can be added to rapid diagnostic assays to effectively diagnose 





Drug resistant tuberculosis (TB) is major public health concern, associated with significant 
morbidity and mortality. The recent emergence of totally drug resistant (TDR) TB, defined as 
strains resistant to all the current first and second line drugs in TB treatment regimens, has 
the potential to completely disrupt TB control programs.(1)  Treatment of multidrug resistant 
(MDR) TB; i.e. strains resistant to isoniazid and rifampicin, relies on the use of second line 
anti-TB drugs such as the fluoroquinolones and injectable aminoglycosides which are less 
effective and have higher toxicities. Additional acquisition of resistance to the second line 
anti-TB drugs defines extensively drug resistant (XDR) TB, associated with poor treatment 
outcomes.(2,3). Given the paucity of new drugs available for the treatment of XDR-TB, it is 
imperative that Mycobacterium tuberculosis isolates from patients must be tested for 
susceptibility to anti-TB drugs to ensure appropriate treatment choices are made and to 
prevent further resistance.(4) Two such drugs, para-amino salicylic acid (PAS) and Linezolid 
(LIN) are treatment options for XD-TB in our setting. Resistance to each of these drugs, 
although rare, are believed to be mediated through mutations in the thyA (5,6) and rrl (7) 
genes, respectively.  Recent studies have demonstrated improved treatment outcomes in 
patients with complicated MDR and XDR when treated with LIN.(8) The aim of this study 
was to screen clinical isolates of M.tuberculosis for mutations in the rrl and thyA genes 
associated with resistance LIN and PAS respectively.  
Materials and Methods: 
Clinical Isolates 
The M. tuberculosis H37Rv laboratory strain and 60 stored clinical isolates, collected from 
2005-2009 at the Church of Scotland Hospital in the Tugela Ferry region of KwaZulu-Natal 
were selected from the culture collection from the Infection Control laboratory, University of 
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KwaZulu-Natal. The samples represented varying antibiotic resistance patterns, comprising 
10 drug susceptible (DS), 17 multi-drug resistant (MDR-TB) and 30 extensively drug 
resistant (XDR-TB) isolates. Genotyping and drug susceptibility profiles were determined 
previously in our laboratory, using standard mycobacteriology protocols. Ethics approval for 
the study was obtained from the Biomedical Research Ethics Committee at the University of 
KwaZulu-Natal (BREC 247/09). DNA was isolated from the cultures using the CTAB-NaCl 
(Cetyl-trimethyl-ammonium Bromide-Sodium Chloride) method, as previously described. (9)  
PCR Amplification and Sequencing 
PCR assays for the rrl gene was conducted as previously described.(7) Primers for thyA gene; 
FWD GCCTCCGTTGTACTCCTGTG and REV TGTCGCCCAATACTTTTTCTACGC; 
were designed for the current study and amplified using the Expand High Fidelity PCR kit 
(Roche) according to the kit guidelines, with annealing temperature of 60◦C. Each PCR 
yielded amplicons of 835bp and 850bp, respectively. PCR amplicons were verified on a 1% 
agarose gel and purified using the Invitrogen PureLink PCR purification kit (Applied 
Biosystems). Direct single stranded sequencing of the amplicons were conducted using ABI 
Prism Big Dye Terminator cycle sequencing kit V3.1 (Applied Biosystems) with the forward 
primers used for PCR amplification. The reactions were cycled in accordance with the 
manufacturer’s guidelines.  Sequence chromatograms were analysed for the presence of 
mutations by comparison of the corresponding reference sequence of the H37Rv reference 
strain using Geneious V5.5.7 sequence analysis software program.  
Results and Discussion 
Three XDR-TB isolates failed multiple attempts at amplification of the rrl gene and were 
excluded from the analysis. 
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 The mutations detected in the study were of 2 types: (1) A → G substitution at position 604 
of the thyA gene (Thr202Ala) and (2) G → A substitution at position 2399 of the rrl gene. 
Both these mutations were detected in 5 MDR-TB isolates and all the XDR-TB isolates 
screened. All isolates with the mutations belonged to the F15/LAM4/KZN strain. Table 6.1 
shows the frequency of the mutations detected and the associated genotypes. The former, 
Thr202Ala, initially implicated in PAS resistance, is now believed to be a phylogenetic 
marker for the Latin American Lineage (LAM) strain.(10) The results of this study support 
the latter findings. The G2399A mutation of the rrl gene has been reported in isolates from 
Brazil and South Africa in 2004 (Listed on the Broad Institute TB mutation database). More 
recently, a study conducted in our laboratory  reported this mutation in drug susceptible (DS) 
and resistant isolates demonstrating that this mutation does not mediate LIN resistance.(11) 
The isolates analysed in the study all belonged to the F15/LAM4/KZN strain. We postulate 
that this mutation maybe a marker for this strain type rather than a resistance mutation.  
Moodley et al. also demonstrated that the KZN XDR-TB isolates are still eligible for 
treatment by the drugs. Time kill data demonstrated that PAS was effective against 50% of 
the drug resistant isolates while LIN was effective against 80% of the drug resistant 
isolates.(11) However, the use of these drugs should be applied in the presence of drug 
susceptibility tests. Alternate mechanisms of drug resistance such as efflux pumps and 
mutations in other target genes have been proposed in the resistance of LIN. Richter et al. 
demonstrated a reduction in the MIC of LIN in the presence of efflux pump inhibitor, 
reserpine.(7) Mutations in the rplC gene, encoding the 50S ribosomal protein L3 in in-vitro 
selected mutants and clinical isolates have also been implicated in LIN resistance. These 
mechanisms require further validation.(1)  
In the case of PAS, no resistance mutations were detected in the thyA gene amongst isolates 
of the KZN strain family. (11) This is in contrast to the report where the Thr202Ala mutation 
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was reported as a specific marker of the LAM lineage. The role of folC gene mutations has 
been implicated in PAS resistance and requires further validation. (12)Resistance 
mechanisms to PAS remains uncertain, with about  40% of resistance attributed to thyA 
mutations.(1,13) LIN is currently included in newer drug resistant TB treatment regimens 
under evaluation in clinical trials. With proven clinical efficacy against MDR and XDR-TB, 
the utility of these drugs need to be preserved in order to effectively treat drug resistant 
tuberculosis.(8)  
Conclusion 
The absence of proven resistance mechanisms of LIN and PAS underscores the need for 
more effective screening of novel targets and detection of resistance mechanisms that can be 
added to rapid diagnostic assays to effectively diagnose and detect drug resistance 
concurrently. 
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Table 6.1: Mutations in the thyA and rrl genes and their associated genotypes in clinical 
isolates of M. tuberculosis.  
Strain 
Classification 











DS 10/10 0 10/10 0 - 
MDR 12/17 5/17 12/17 5/17 F15/LAM4/KZN 






















Efflux mediated drug resistance in clinical isolates of Mycobacterium tuberculosis in 
KwaZulu-Natal, South Africa. 
Short Communication 
Abstract 
The global dissemination of drug resistant phenotypes of Mycobacterium.tuberculosis has 
turned the most effective anti-tuberculosis drugs currently available for the treatment of 
tuberculosis, ineffective in a subset of patients. Efflux mediated resistance in M.tuberculosis 
has emerged as a significant factor in drug resistance. Efflux pumps mediate the extrusion of 
antibiotics from the bacterial cell, allowing for the establishment of resistance conferring 
mutations, resulting in selection of resistant mutants. In this study, we assessed the role of 
efflux pumps in drug resistance of M.tuberculosis. We analysed a panel of clinical isolates 
that displayed low-level resistance to isoniazid, rifampicin, ciprofloxacin, moxifloxacin and 
kanamycin. In the presence of the efflux pump inhibitors reserpine, verapamil and 
thioridazine, a reduction in the MICs was observed. We provide evidence that efflux pumps 
mediate low-level drug resistance in clinical isolates from our setting. The results of this 
study support further studies to assess the effect of efflux pump inhibitor compounds as 
adjunctive treatment for drug resistant tuberculosis. 
Text 
Antimicrobial resistance in M.tuberculosis has been attributed to several mechanisms 
including mutations in genes coding for drug targets, decreased cell wall permeability and 
increased efflux pump activity. The role of efflux pump activity has recently been recognized 
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as a significant factor in the natural resistance in mycobacteria.1,2 In contrast to the high-level 
resistance resulting from genetic mutations leading to altered drug targets, increased efflux 
activity has been associated with low-level resistance.3 The decreased intracellular antibiotic 
concentration as a result of efflux, promotes the survival of a sub-population of bacteria 
exposed to sub-inhibitory levels of the antibiotic. This sub-population acquires resistance 
conferring mutations, leading to clinically significant levels of resistance.4–6Studies have 
reported the association of efflux pumps in low-level resistance to isoniazid (INH), 
rifampicin (RIF), aminoglycosides, fluoroquinolones, streptomycin, linezolid, tetracycline 
and chloramphenicol.7–15 Efflux pump inhibitor (EPI) compounds, like  reserpine (RES), 
verapamil (VERA) and thioridazine (THIO) have the ability to restore the activities of 
antibiotics.13,16–20 They also have the ability to reduce the minimum inhibitory concentration 
(MIC) of anti- tuberculosis (TB) drugs, potentially reducing the dosage requirements for 
treatment. This could assist in decreasing the toxicity associated with second line anti- TB 
drugs.21 The value of EPIs as adjunct therapy in TB treatment has been tested in patients and 
has shown potential to reduce the current treatment duration and has been effective in the 
treatment of multidrug resistant (MDR) and extensively drug resistant (XDR) TB.16 The aim 
of this study was to assess the potential of RES, VERA and THIO in reducing the MICs of 
the key anti-TB drugs in M.tuberculosis isolates from KwaZulu-Natal, South Africa. M. 
tuberculosis H37Rv and stored clinical isolates were selected from the culture collection of 
the Infection Control laboratory, University of KwaZulu-Natal. The isolates selected for the 
study were MDR-TB isolates that displayed an increased MIC when compared to the DS 
isolates, but lacked the mutations in drug targets that were responsible for drug resistance in 
the XDR-TB isolates. These isolates subjected to MIC determination in the presence of RES 
(80mg/L)22, VERA (50mg/L)22 and THIO (16mg/L)17 together with each of the antibiotics. 
The selected range of drug concentrations was based on the MIC of the isolates in the 
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absence of EPIs and reflects one concentration above and four below the MIC of each of the 
drugs. The MICs were determined in Middlebrook 7H10 agar medium supplemented with 
oleic acid-albumin-dextrose-catalase (OADC) using the agar dilution technique in quadrant 
petri dishes. Bacterial cultures were prepared by adjusting the bacterial suspension to give a 
turbidity equivalent to that of a 1.0 McFarland standard and then diluted to obtain a final 
bacterial density of 1 x 103 colony forming units per ml. One hundred microliters was 
inoculated on each quadrant of the Middlebrook 7H10 agar plates with drug concentrations 
ranging from 0.25 to 8 mg/L for INH, RIF and kanamycin (KAN) and from 0.06 to 2 mg/L 
for ciprofloxacin (CPX) and moxifloxacin (MXF). EPIs were added at their respective 
concentrations to detect a change in MIC. Plates were incubated in a CO2 enriched 
atmosphere at 37ºC for 21 days.  The MIC was defined as the lowest antibiotic concentration 
that resulted in a complete inhibition of growth. In the case of RIF, one of the isolates tested 
failed to grow and the second isolate tested recorded an MIC higher than its initial RIF MIC, 
thereby displaying growth at all concentrations. Therefore, we could not assess the change in 
MIC in this isolate. The INH MIC was reduced 3 to 4 fold in the presence of RES, 2 fold in 
the presence of VERA and 3 fold in the presence of THIO. In the case of the H37Rv 
laboratory strain, growth was only observed in the drug free medium control, indicating that 
the MIC for INH was < 0.25mg/L. All 3 EPIs reduced the MIC of KAN by 1 fold for the 2 
clinical isolates tested. The MIC of the H37Rv lab strain was decreased by 1 fold in the 
presence of RES and VERA and 3 fold or more in the presence of THIO. RES failed to alter 
the MIC for MXF, whilst VERA reduced the MIC by 1 fold. The MIC for THIO were 
reduced 3 fold or more. In the case of H37Rv, growth was only observed in the drug free 
medium control, indicating that the MIC for MXF was < 0.06mg/L. In the case of CPX, one 
isolate failed to grow when sub cultured onto the MIC media. The MIC of the remaining 
clinical isolate, was decreased 3 folds in the presence of VERA and RES and 1 fold for 
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THIO. The MIC of H37Rv was decreased more than 3 folds in the presence of RES and 1 
fold with VERA and THIO. The change in MIC for each of the drugs tested is shown in table 
7.1. The results of this study demonstrate that efflux pumps, in addition to genetic mutations 
play a role in drug resistance in the clinical isolates from our setting. Studies have 
demonstrated that efflux pump activity results from exposure to decreased concentrations of 
a drug allowing for M.tuberculosis bacilli to survive. This subsequently leads to the selection 
of mutants resulting in high-level resistance.23–25 The isolates analysed in the current study 
displayed low-level resistance in the absence of mutations. Based on WHO guidelines, we 
also demonstrated the ability of EPIs to reverse the resistance induced by efflux activity.26 
RES restored INH susceptibility, all 3 EPIs restored KAN and CPX, and VERA and THIO 
restored MXF susceptibility. Given the current paucity of effective drugs available for 
treatment of drug resistant TB, the possible role of these agents as adjunct therapy is 
encouraging. THIO has shown effective activity against MDR and XDR TB strains in vitro 
and in mice.27 THIO in combination with MXF and LIN was recently evaluated in XDR TB 
patients on the basis of compassionate use. The combination was associated with cure, free of 
relapse. The addition of THIO was also associated with earlier bacteriological sputum 
conversion. 16 Recent reports have provided compelling evidence that the addition of 
verapamil as an adjunct to treatment with bedaquiline, a newly introduced anti-TB drug will 
aid in reducing the MIC of bedaquiline. As a result the amount of the drug to be administered 
per dose could be decreased decreasing the chance of cardiac morbidity associated with the 
drug. 21,28 The application of EPIs to current regimens has been reported to shorten the 
duration of treatment. This has important implications for patient adherence and will 
significantly impact on treatment outcomes. 17,29,30 Of significance, EPIs can be applied to TB 
treatment, independently of the level of resistance of the organism.17 In conclusion, we 
127 
 
provide proof of concept that efflux pumps mediate low-level resistance in our setting and 
support further exploration of efflux pump inhibitors for treatment of TB. 
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Table 7.1: MICs in the presence of efflux pump inhibitors. 
Isoniazid MICs (mg/L) 
Isolate INH RES VERA THIO 
MODS 39 2 < 0.25 0.5 0.25 
MODS 11 4 < 0.25 1 0.5 
H37Rv < 0.25 < 0.25 < 0.25 < 0.25 
Rifampicin MICs (mg/L) 
Isolate RIF RES VERA THIO 
TF44949 > 8 > 8 > 8 > 8 
MODS11 NG NG NG NG 
H37Rv < 0.25 < 0.25 < 0.25 < 0.25 
Kanamycin MICs (mg/L) 
Isolate KAN RES VERA THIO 
TF 44949 4 2 2 2 
MODS 11 4 2 2 2 
H37Rv 2 2 2 < 0.25 
Ciprofloxacin MICs (mg/L) 
Isolate CPX RES VERA THIO 
TF 64747 1 0.125 0.125 0.25 
TF 3228 2 NG NG NG 
H37Rv 0.5 < 0.06 0.25 0.25 
Moxifloxacin MICs (mg/L) 
Isolate MXF RES VERA THIO 
MODS 11 0.5 0.5 0.25 < 0.06 
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TF 3181 0.5 0.5 0.25 < 0.06 






























Drug resistant TB is one of the key public health challenges of modern times. The 
devastating emergence of drug resistant forms of the disease is attributed to the ability of 
M.tuberculosis to adapt and evolve under antimicrobial pressure. To tackle the management 
of patients with drug resistant TB, we must understand the dynamics of antimicrobial 
resistance and the complexity of the mechanisms mediating resistance in M.tuberculosis.  
Analysis of the various genes linked to drug resistance in M.tuberculosis, has revealed that 
the strains circulating in our setting display a combination of previously observed mutations. 
Each of these mutations results in resistance to a different drug. This supports previous 
reports that there is no single pleiotropic mutation resulting in the MDR phenotype, but rather 
an accumulation of mutations in the genome of M.tuberculosis. However, a complex 
association between resistance mutations are believed to exist. Classical mutations associated 
with resistance to one drug is thought to be the initial step that leads to resistance to other 
drugs. (1)  
The MDR and XDR-TB strains analysed in this study displayed classical mutations in the 
katG, embB, gyrA and rrs genes, responsible for resistance to INH, EMB, fluoroquinolones 
and aminoglycosides respectively. The diversity of the mutations in the rpoB and pncA 
genes, responsible for resistance to RIF and PZA, demonstrates that MDR phenotype  is due 
to de novo resistance.(2) The high level of similarity amongst the XDR-TB strains, with the 
predominance of the F15/LAM4/KZN strain supports previous reports regarding the clonality 
of the XDR epidemic in KZN. The F15/LAM4/KZN strain is a highly virulent strain, 
endemic to our setting. The strain has successfully disseminated amongst immune 
compromised patients with HIV co-infection.(3,4)  
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The results of this study demonstrates that the rare 130bp deletion of the gidB gene is lineage 
specific, observed in only the F15/LAM4/KZN strain family. Whilst the deletion has been 
previously described, we demonstrate this deletion exclusively in MDR and XDR-TB strains 
of the KZN lineage from our setting.(2) In contrast to reports that attribute low-level STR 
resistance induced by mutations in the gidB gene, our results demonstrate that alteration 
within this gene mediates high-level STR in this subset of clinical isolates.(5–7) Furthermore, 
classical mutations in the rpsL and rrs genes previously described, were only found in 18.9% 
of the STR resistant isolates in this study.(5,7–11) Our results also demonstrates the inability 
of the mutations to discriminate between various levels of STR resistance. The low detection 
rate of the rpsL and rrs mutations in this subset of isolates questions the utility of these 
mutations as accurate predictors of STR resistance. 
Whilst the WHO does not define resistance beyond XDR-TB, reports of isolates resistant to 
all first and second line drugs has been termed TDR-TB.(12–14) The XDR TB isolates 
analysed in this study are characteristic of TDR-TB. The presence of the A90V gyrA 
mutation correlates with high-level resistance to CPX and OFX, and an increased MXF MIC 
in the XDR TB clinical isolates analysed. Although the breakpoint concentration for MXF 
remains debatable, we raise concerns regarding the application of the drug to XDR-TB 
treatment protocols. MXF is added to treatment protocols despite reports of in vitro 
resistance, with the hope that there may be some residual activity. This is disastrous from a 
public health perspective, in the era of ever-increasing drug resistance.   
We also demonstrate the presence of the A1401G rrs mutation and its correlation with high 
level resistance to KAN and AMIK and a decreased susceptibility to CAP in the isolates 
analysed. We support the WHO revised breakpoint concentration of 4mg/L for CAP, this will 
prevent patients from receiving inadequate treatment that could lead to the development of 
further resistance as well as continued transmission.(12)  
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Screening of drug drugs of LIN and PAS revealed no genetic alteration that indicates drug 
resistance. Therefore, the strategic application of LIN and PAS is central to the treatment of 
drug resistant tuberculosis in our setting, as the strains may still be accessible for treatment 
with these drugs.  
The XDR-TB isolates analyzed here displayed resistance to the fluoroquinolones and 
aminoglycosides, the most effective second line anti-TB drugs available for the treatment of 
drug resistant TB. Therefore, appropriate application of these agents is central to the effective 
management of MDR-TB and prevention of XDR-TB. It is imperative that MDR-TB patients 
are first tested to ensure that they are eligible for treatment to ensure appropriate treatment 
choices are made and to prevent the further amplification of drug resistance.(15) 
We also demonstrate that efflux mediated resistance results in low-level resistance in the 
absence of mutations. Efflux mediated resistance in M.tuberculosis has emerged as a 
significant factor mediating drug resistance. Efflux pumps allow the extrusion of antibiotics 
from the bacterial cell, resulting in selection of resistant mutants. We also demonstrated the 
ability of EPIs to reverse the resistance induced by efflux activity, providing proof of concept 
that efflux pumps mediate low-level resistance in our setting and support further exploration 
of efflux pump inhibitors for treatment of TB. 
Antibiotic exposure induces a complex response in M.tuberculosis, including changes in 
metabolic state and activity that contributes to resistance. Recent reports have implicated a 
number of mechanisms in resistance, demonstrating the complexity of resistance in the 
organism. Alteration in DNA repair systems, resulting in a reduced ability to repair DNA, 
results in increased mutation rates. Such mutator phenotypes have a selective advantage 
under antibiotic pressure. Compensatory evolution has allowed the organism to adapt by 
eliminating the fitness cost associated with mutations. Recent studies have demonstrated that 
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laboratory generated mutants were less fit than clinical strains, demonstrating the role of 
compensatory mechanisms.(16) 
 In South Africa, the public health service faces major barriers in the control of TB. The 
active transmission of drug resistant phenotypes, HIV co-infection, complex treatment 
regimens associated with higher toxicity and the duration of treatment have impacted on the 
poor control of TB. (17)Although drug resistance accounts for approximately 3% of all TB 
cases, it consumes more than a third of the national budget for TB, which is unsustainable 
and further threatens to destabilize control.(18)  
Early diagnosis and treatment with antimicrobials known to be effective against the infecting 
strain, coupled with infection prevention measures remain the primary strategy in TB control. 
The Xpert MTB/RIF assay has assisted somewhat in this strategy. However, susceptibility is 
only obtained for one drug. Expansion of this test platform to include other drugs would 
assist in making an early diagnosis as well as allowing for patient individualized selection of 
antimicrobial agents. Whole genome sequencing technology has increased our capacity to 
understand the disease and may be the only hope in detecting resistance to multiple drugs. 
(19) There has been no greater need for new rapid diagnostic tests, antimicrobial tests and 
anti-TB drugs or regimens than the present. Recent focus has shifted to investigating adjunct 
treatment options, known as host directed therapy with the aim to enhance host immune 
responses against M.tuberculosis infection, reduce excessive inflammation, prevent and 
repair tissue damage and enhance the effectiveness of current treatment regimens.(17)  
Whilst new developments offer a ray of hope, they are years away from integration into TB 
programmes. Thus strengthening the public health systems and strategic use of current anti-
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DNA Extraction Solutions 
1.1 10x TE Buffer 
Trizma base (Sigma-Aldrich, USA) 1.21g 
EDTA (Sigma-Aldrich, USA) 0.37g 
Weigh out the required amounts of reagent powders and dissolve the trizma base in 80ml 
of distilled water, pH to 8 using concentrated HCl (Merck). Add the EDTA and dissolve. 
Check the final pH and adjust to a final volume of 100ml. Autoclave at 121°C for 15 
minutes. 
 
1.2 Lysozyme (10mg/ml) (Sigma-Aldrich, USA) 
Add 1ml of distilled water to 10mg of lysozyme powder. Store at 4°C until 
 
1.3 Proteinase K (10mg/ml) (Roche Diagnostics) 
Add 10ml of distilled water to 100mg of proteinase K powder. Store at 4°C until. 
 
1.4 10% Sodium Dodecyl Sulfate (SDS) (Sigma-Aldrich, USA) 
Weigh 10g of SDS powder and dissolve in 100ml of distilled water. 
 
1.5  5M Sodium Chloride (NaCl) (Sigma-Aldrich, USA) 
Weigh 14.6 g of NaCl powder and dissolve in 50ml of distilled water, autoclave at 121°C 




1.6 CTAB-NaCl Solution 
 
NaCl (Sigma-Aldrich, USA) 4.1g 
CTAB (Sigma-Aldrich, USA) 10g 
 
 
Weigh out the required amounts of reagent powders and dissolve in 100ml of distilled 
water, the solution is heated to 65°C until powders are completely dissolved. 
1.7 Chloroform: Isoamyl alcohol (24:1) 
Add 1ml of isoamyl alcohol (Sigma-Aldrich, USA) to 24ml of chloroform (Sigma-Aldrich, 
USA. 
 
1.8 70% ethanol 
Add 35ml of absolute ethanol (Merck, SA) to 15ml of distilled water.  Store at -20°C. 
 
1.9  1% agarose gel (140ml) 
 
Agarose powder (Lonza, USA) 1.4g 
 
1x TBE buffer 140ml 
 
Ethidium bromide 140µl 
 
 
The agarose powder was weighed and added to a flask containing 1x TBE buffer. The 
mixture was boiled using a microwave until the powder dissolved. It was allowed to cool 




1.10 10xTBE Buffer 
 
Trizma base (Sigma-Aldrich, USA) 108g 
Boric acid (Sigma-Aldrich, USA) 55g 
EDTA (Sigma-Aldrich, USA) 9.3g 
 
Weigh out the required amounts of the reagents and dissolve in 1000ml of distilled water. 
 
1.11 Sample loading dye 
 
1% Double dye 
 
Bromphenol Blue (Sigma-Aldrich, USA)   1g 
Xylene cyanole (Sigma-Aldrich, USA) 1g 
 
Weigh out the required amounts of reagent powders and dissolve in 100ml of distilled 
water. 
50 ml of Loading Dye from 1% Double Dye (DD) stock: 
10x TBE 5 ml 
Glycerol (Merck, SA) 25 ml 
1% Double dye 5 ml 
 









Media and Reagents 
 
2.1 Middlebrook 7H9 broth (Difco) 
4.7g Middlebrook 7H9 powder 
100ml OADC (BD) 
10ml 50% (w/v) glycerol 
2.5ml 20% Tween 80 
4.7g of Middlebrook 7H9 powder was dissolved in approximately 800ml of autoclaved 
distilled water together with 10ml of 50% (w/v) glycerol, 2.5ml of 20% Tween 80 and was 
autoclaved at 121oC for 15 minutes. The solution was placed in preheated water bath set to 
50oC to cool with gentle swirling for approximately 30 minutes and 100ml of OADC was 
added. 
 
2.2 Middlebrook 7H11 solid agar (Difco) 
21g Middlebrook 7H11 powder  
100ml OADC (BD) 
10ml 50% (w/v) glycerol 
Twenty-one grams of Middlebrook 7H11 powder was dissolved in 900ml of triple distilled 
water and autoclaved at 121oC for 15 minutes. The solution was placed in preheated 
water bath set to 50oC to cool with gentle swirling for approximately 30 minutes. 




2.3 Phosphate buffered saline (PBS) (Oxoid) 
10 PBS tablets  
1000ml distilled water 
Ten PBS tablets were dissolved in 1000ml autoclaved distilled water. The PBS was 
autoclaved at 121oC for 15 minutes, thereafter decanted into 20ml aliquots and refrigerated at 
4oC until use. 
2.4 20%Tween 80 (Fisher) 
20ml Tween 80  
80ml distilled water 
20ml of Tween 80 (Fisher) was added to 80ml of autoclaved distilled water. The solution was 












Appendix 3: IS6110 RFLP patterns 
 
Figure A 3.1 is a scanned hyperfilm showing the IS6110 RFLP patterns obtained in the 
study 
     M    2     3     4      5 6     7     8        9    10   11   12   13    14    15 
 
 
Figure 1: IS6110 RFLP patterns for (2005-2006) and (2008-2009) 
Lane 1: Jack‘s standard molecular weight marker (0.7-15kbps) 
(2005-2006):  Lane 2-3: unique cluster Lane 12: unique patterns 
Lane 4-8: F15/LAM4/KZN family patterns Lane 13: Beijing family pattern 
Lane 9-11: F28 family patterns 
(2008-2009): Lanes 14-15: unique patterns 
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Figure A  3 . 2  Dendogram generated for the IS6110 RFLP patterns. The 



















Figure A 3.2.1: IS6110 RFLP patterns (2005-2006) 
       M    2     3     4      5   6     7     8        9    10   11   12   13  14  15   16    17   18  M 
 
 
IS6110 RFLP patterns (2005-2006) 
Lane 1 & 19: Jack‘s standard molecular weight marker (0.7-15 kbps) 
Lane 2 & 10: Beijing family patterns 
Lane 3: F28 family pattern 
Lane 5: unique pattern 
Lane 6-9, 11-18: F15/LAM4/KZN family patterns 
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Figure A 3.2.2: IS6110 RFLP patterns (2005-2006) 
      M    2     3     4      5   6     7     8        9    10   11   12   13  14  15   16    17   18     19   20 
 
 
IS6110 RFLP patterns (2008-2009) 
 
Lane 1 & 19: Jack‘s standard molecular weight marker (0.7-15 kbps) 
Lane 2-4, 6, 8, 10-11, 13-18, 20: F15/LAM4/KZN family patterns 
Lane 5, 7, 12: F28 family patterns 
Lane 9: unique pattern 
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Figure A 3.2.3: IS6110 RFLP patterns (2005-2006) 
     M    2     3     4      5   6     7     8        9    10   11   12   13  14  15   16    17    18     19   20 
 
 
IS6110 RFLP patterns (2005-2006) 
 
Lane 1 & 19: Jack‘s standard molecular weight marker (0.7-15 kbps) 
Lane 2, 6, 8, 11: F28 family patterns 
Lane 3, 5, 7, 9, 12, 18: F15/LAM4/KZN family patterns 
 
Lane 4, 10, 13, 14, 16, 17, 20: unique patterns 
Lane 15: Beijing family patterns. 
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Figure A 2.3.4: IS6110 RFLP patterns (2005-2006) 
          M    2     3     4      5      6     7     8   9    10   11   12   13  14  15   16    17   M   18 
 
 
IS6110 RFLP patterns (2005-2006) 
 
Lane 1& 17: Jack‘s standard molecular weight marker (0.7-15 kbps) 
Lane 2-3, 5-6, 8-13, 15: F15/LAM4/KZN family patterns 
Lane 4 & 16, 18: F28 family patterns 
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Figure 3e: IS6110 RFLP patterns for (2005-2006) and (2008-2009) 
      M    2     3     4      5   6     7     8  9    10   11   12   13  14  15   16    17   18  19   20 
 
 
IS6110 RFLP patterns for (2005-2006) and (2008-2009) 
Lane 1 & 19: Jack‘s standard molecular weight marker (0.7-15 kbps) 
(2005-2006): lane 2-3 F15/LAM4/KZN family patterns 
Lane 4: F28 family patterns, 
Lane 5-7: unique patterns 
(2008-2009): 




Appendix 4: Data tables of MIC, PCR and Sequence Results  
Table A 4.1: MIC, RFLP and sequencing data for INH, EMB and PZA 
MIC’s for PZA was not done 
∆C = insertion of cytosine 
- = no mutation 




























inhA katG embB pncA 
  INH EMB   944 1343 1388 916 1489 100 416 457 
TF1538 U ≤0.125 2 - - - - - - - - - - 
TF1413 B 16 2 - - - - G-T - - - - - 
TF1582 B ≤0.125 2 - - - - G-T - - - - - 
TF832 F11V ≤0.125 2 - - - - - - - - - - 
TF1519 B ≤0.125 2 - - - - - - - - - - 
TF1001 U ≤0.125 2 - - - - - - - - - - 
TF933 U ≤0.125 2 - - - - - - - - - - 
P090811 B ≤0.125 2 - - - - G-T - - - - - 
P090802 B ≤0.125 2 - - - - G-T - - - - - 
P090804 B ≤0.125 2 - - - - G-T - - - - - 
H37Rv    - - - - - - - - - - 
 
MDR RFLP INH EMB   944 1343 1388 916 1489 100 416 457 
MODS11 KZN 8 8 - - G-C - - A-G - - - ∆C 
MODS688 KZN 8 8 - - G-C - - A-G - - T-G - 
TF44949 F28 16 8 - - G-C - - A-G - - - - 
TF3251 KZN 16 16 - - G-C - - A-G - - - - 
TF78838 F28 16 8 - - G-C - - A-G - T-G - - 
TF2063 F28 16 16 - - G-C - - A-G - T-G - - 
TF3203 F28 16 16 - - G-C - - A-G - T-G - - 
TF1951 F28V 16 16 - - G-A - - A-G - - - - 
TF64747 KZN 16 8 - - G-C - - A-G - - T-G - 
MODS644 F28 16 8 - - G-C - - A-G -    
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TF2889 F28 16 8 - - G-C - - - C-A - - - 
TF2040 F28 16 16 - - G-C - - - C-A T-G - - 
MODS682 F28 16 16 - - G-C - - - - - - - 




inhA katG embB pncA 
  INH EMB   944 1343 1388 916 1489 100 416 457 
TF36480 KZN 16 8 - - G-C - - A-G - T-G - - 
TF2034 U 16 16 - - G-C A-C - A-G - - - - 
TF2153 F28 16 16 - - G-C - - A-G - T-G - - 
 
XDR      944 1343 1388 916 1489 100 416 457 
TF1762 KZN 8 16 - - G-C - - A-G - - - ∆C 
MODS141 KZN 8 16 - - G-C - - A-G - - - ∆C 
MODS39 KZN 4 2 - - G-C - - A-G -    
MODS387 KZN 16 8 - - G-C - - A-G - - - ∆C 
MODS338 KZN 16 16 - - G-C - - A-G - - - ∆C 
MODS667 KZN 16 16 - - G-C - - A-G - - - ∆C 
MODS642 KZN 16 16 - - G-C - - A-G - - - ∆C 
MODS513 KZN 8 16 - - G-C - - A-G - - - ∆C 
MODS143 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF1824 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF1925 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF66937 KZN 16 8 - - G-C - - A-G - - - ∆C 
TF3334 KZN 16 8 - - G-C - - A-G - - - ∆C 
TF80198 KZN 16 8 - - G-C - - A-G - - - ∆C 
TF80164 KZN 16 16 - - G-C - - A-G -    
TF1497 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF75549 KZN 16 16 - - G-C - - A-G - - - ∆C 
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TF31066 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF739 KZN 16 16 - - G-C - - A-G - - - ∆C 
MODS370 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF3181 KZN 16 16 - - G-C - - A-G - - - ∆C 





inhA katG embB pncA 
  INH EMB   944 1343 1388 916 1489 100 416 457 
TF37806 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF2981 KZN 16 16 - - G-C - - A-G - - - ∆C 
MODS334 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF2038 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF3228 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF25027 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF51648 KZN 16 16 - - G-C - - A-G - - - ∆C 
TF49127 KZN 16 16 - - G-C - - A-G - - - ∆C 









Table A 4.2: MIC and sequencing data for RIF 
 SUSCEPTIBLE RFLP MIC 
mg/L 
rpoB 
   1303 1304 1334 1349 1355 1360 1473 
TF1538 U 1 - - - - - - - 
TF1413 B 1 - - - - - - - 
TF1582 B 1 - - - - - - - 
TF832 F11V 1 - - - - - - - 
TF1519 B 1 - - - - - - - 
TF1001 U 1 - - - - - - - 
TF933 U 1 - - - - - - - 
P090811 B 1 - - - - - - - 
P090802 B 1 - - - - - - - 
P090804 B 1 - - - - - - - 
H37Rv   - - - - - - - 
 
MDR RFLP  1303 1304 1334 1349 1355 1360 1473 
MODS11 KZN 8 - - -  T-C - - 
MODS688 KZN 128 - - - C-T - - - 
TF44949 F28 32 - - - C-T - - - 
TF3251 KZN 128 G-T - -  - C-A - 
TF78838 F28 128 - - - C-T - - - 
TF2063 F28 128 - - - C-T - - - 
TF3203 F28 128 - - - C-T - - - 
TF1951 F28V 128 - - A-T  - - G-C 
TF64747 KZN 128 - - - C-T - - - 
MODS644 F28 2        
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MDR RFLP MIC 
mg/L 
rpoB 
   1303 1304 1334 1349 1355 1360 1473 
TF2889 F28 64 - - - C-T T-C - - 
TF2040 F28 128 - - - C-T - - - 
MODS682 F28 128 - - - - - - - 
TF36480 KZN 128        
TF2034 U 64 - - - C-T T-C - - 
TF2153 F28 128 - - - - - - - 
 
XDR RFLP  1303 1304 1334 1349 1355 1360 1473 
TF1762 KZN 16 - A-G - - T-C - - 
MODS141 KZN 128 - A-G - - T-C - - 
MODS39 KZN 32 - A-G - - T-C - - 
MODS387 KZN 128 - A-G - - T-C - - 
MODS338 KZN 128 - A-G - - T-C - - 
MODS667 KZN 128 - A-G - - T-C - - 
MODS642 KZN -        
MODS513 KZN 128 - A-G - - T-C - - 
MODS143 KZN 128 - A-G - - T-C - - 
TF1824 KZN 128 - A-G - - T-C - - 
TF1925 KZN 128 - A-G - - T-C - - 
TF66937 KZN 128 - A-G - - T-C - - 
TF3334 KZN -        
TF80198 KZN 128 - A-G - - T-C - - 
TF80164 KZN 128 - A-G - - T-C - - 
TF1497 KZN 128 - A-G - - T-C - - 
TF75549 KZN 128 - A-G - - T-C - - 
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XDR RFLP MIC 
mg/L 
rpoB 
   1303 1304 1334 1349 1355 1360 1473 
TF31066 KZN 128 - A-G - - T-C - - 
TF739 KZN 128 - A-G - - T-C - - 
MODS370 KZN 128 - A-G - - T-C - - 
TF3181 KZN 128 - A-G - - T-C - - 
TF37806 KZN 128 - A-G - - T-C - - 
TF2981 KZN 128 - A-G - - T-C - - 
MODS334 KZN 128 - - - - - - - 
TF2038 KZN 128  A-G - - - - - 
TF3228 KZN 128 - - - - - - - 
TF25027 KZN 128 - A-G - - - - - 
TF51648 KZN 128 - A-G - - - - - 
TF49127 KZN 64 - A-G - - - - - 










Table A 4.3: MIC and sequencing data for STREP 
SUSCEPTIBLE RFLP MIC 
mg/L 
gidB rpsL 
   Del 47 274 299 405 128 363 
TF1538 U 0.5 - - - C-T - - - 
TF1413 B 4 - - - C-T - - - 
TF1582 B 0.5 - - - C-T - - - 
TF832 F11V 0.5 - T-G - C-T - - - 
TF1519 B 0.5 - - - C-T - - - 
TF1001 U 0.5 - - - C-T G-T - - 
TF933 U 0.5 - - - C-T - - - 
P090811 B 0.5 - - A-C C-T - - - 
P090802 B 0.5 - - A-C C-T - - - 
P090804 B 0.5 - - A-C C-T - - - 
H37Rv  0.5 - - - - - - - 
 
MDR RFLP  Del 47 274 299 405 128 363 
MODS11 KZN 128 Present T-G Del C-T - - - 
MODS688 KZN 128 Present T-G Del C-T - - - 
TF44949 F28 128 - - A-C C-T - A-G - 
TF3251 KZN 128 Present T-G Del C-T - - - 
TF78838 F28 4 - - A-C C-T - A-G - 
TF2063 F28 4 - - A-C C-T - A-G - 
TF3203 F28 4 - - A-C C-T - A-G - 
TF1951 F28V 4 - - A-C C-T - - - 
TF64747 KZN 32 Present T-G Del C-T - - - 
MODS644 F28 4 - - A-C C-T - - - 
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TF2889 F28 -        
MDR RFLP MIC 
mg/L 
GidB rpsL 
   Del 47 274 299 405 128 363 
TF2040 F28 4 - - A-C C-T - A-G - 
MODS682 F28 8 - - A-C C-T - - - 
TF36480 KZN 4 - - A-C C-T - A-G - 
TF2034 U -        
TF2153 F28 4 - - A-C C-T - A-G - 
 
XDR   Del 47 274 299 405 128 363 
TF1762 KZN 12328 Present T-G Del C-T - - A-G 
MODS141 KZN 1284 Present T-G Del C-T - - A-G 
MODS39 KZN 4128 Present T-G Del C-T - - A-G 
MODS387 KZN 44 Present T-G Del C-T - - A-G 
MODS338 KZN 432 Present T-G Del C-T - - A-G 
MODS667 KZN 4 Present T-G Del C-T - - A-G 
MODS642 KZN 128 Present T-G Del C-T - - A-G 
MODS513 KZN 128 Present T-G Del C-T - - A-G 
MODS143 KZN 4 Present T-G Del C-T - - A-G 
TF1824 KZN 128 Present T-G Del C-T - - A-G 
TF1925 KZN 4 Present T-G Del C-T - - A-G 
TF66937 KZN 32 Present T-G Del C-T - - A-G 
TF3334 KZN 128 Present T-G Del C-T - - A-G 
TF80198 KZN 32 Present T-G Del C-T - - A-G 
TF80164 KZN 128 Present T-G Del C-T - - A-G 
TF1497 KZN 32 Present T-G Del C-T - - A-G 
TF75549 KZN 128 Present T-G Del C-T - - A-G 
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TF31066 KZN 128 Present T-G Del C-T - - A-G 
TF739 KZN 4 Present T-G Del C-T - - A-G 
XDR RFLP MIC 
mg/L 
gidB rpsL 
   Del 47 274 299 405 128 363 
MODS370 KZN 32 Present T-G Del C-T - - A-G 
TF3181 KZN 128 Present T-G Del C-T - - A-G 
TF37806 KZN 128 Present T-G Del C-T - - A-G 
TF2981 KZN 128 Present T-G Del C-T - - A-G 
MODS334 KZN 4 Present T-G Del C-T - - A-G 
TF2038 KZN 128 Present T-G Del C-T - - A-G 
TF3228 KZN 128 Present T-G Del C-T - - A-G 
TF25027 KZN 128 Present T-G Del C-T - - A-G 
TF51648 KZN 4 Present T-G Del C-T - - A-G 
TF49127 KZN 128 Present T-G Del C-T - - A-G 










Table A 4.4: MIC and sequencing data for KANA, AMIK and CAP 
SUSCEPTIBLE RFLP MIC 
mg/L 
Rrs tlyA eis 
promoter 
eis 
  KANA AMI CAP 500 1400 33   
TF1538 U 2 1 4 - - A-G - - 
TF1413 B 2 2 4 - - A-G - - 
TF1582 B 2 2 4 - - A-G - - 
TF832 F11V 2 2 4 - - A-G - - 
TF1519 B 2 2 4 - - A-G - - 
TF1001 U 2 2 4 - - A-G - - 
TF933 U 4 2 4 - - A-G - - 
P090811 B 2 1 4 - - A-G - - 
P090802 B 2 1 4 - - A-G - - 
P090804 B 2 1 4 - - A-G - - 
H37Rv  2 1 4 - - - - - 
 
MDR RFLP KANA AMI CAP 500 1400 33   
MODS11 KZN 4 2 4 - - A-G - - 
MODS688 KZN 4 2 4 - - A-G - - 
TF44949 F28 2 1 4 - - A-G - - 
TF3251 KZN 4 2 8 - - A-G - - 
TF78838 F28 2 2 4 - - A-G - - 
TF2063 F28 4 2 4 - - A-G - - 
TF3203 F28 2 1 4 - - A-G - - 
TF1951 F28V 2 1 4 - - A-G - - 
TF64747 KZN 2 2 4 - - A-G - - 
MODS644 F28 2 2 4 - - A-G - - 
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TF2889 F28 2 2 4 - - A-G - - 
MDR RFLP MIC 
mg/L 
Rrs tlyA eis 
promoter 
eis 
  KANA AMI CAP 500 1400 33   
TF2040 F28 2 2 4 - - A-G - - 
MODS682 F28 2 1 4 - - A-G - - 
TF36480 KZN 2 1 4 - - A-G - - 
TF2034 U 4 2 4 - - A-G - - 
TF2153 F28 2 2 4 - - A-G - - 
XDR  KANA AMI CAP 500 1400 33   
TF1762 KZN >128 >128 >16 - A-G A-G - - 
MODS141 KZN >128 >128 >16 - A-G A-G - - 
MODS39 KZN >128 >128 >16 - A-G A-G - - 
MODS387 KZN >128 >128 >16 - A-G A-G - - 
MODS338 KZN >128 >128 >16 - A-G A-G - - 
MODS667 KZN >128 >128 >16 - A-G A-G - - 
MODS642 KZN >128 >128 >16 - A-G A-G - - 
MODS513 KZN >128 >128 >16 - A-G A-G - - 
MODS143 KZN >128 >128 >16 - A-G A-G - - 
TF1824 KZN >128 >128 >16 - A-G A-G - - 
TF1925 KZN >128 >128 >16 - A-G A-G - - 
TF66937 KZN >128 >128 >16 - A-G A-G - - 
TF3334 KZN >128 >128 16 - A-G A-G - - 
TF80198 KZN >128 >128 16 - A-G A-G - - 
TF80164 KZN >128 >128 16 - A-G A-G - - 
TF1497 KZN >128 >128 >16 - A-G A-G - - 
TF75549 KZN >128 >128 >16 - A-G A-G - - 
TF31066 KZN >128 >128 >16 - A-G A-G - - 
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  KANA AMI CAP 500 1400 33   
MODS370 KZN >128 >128 >16 - A-G A-G - - 
TF3181 KZN >128 >128 >16 - A-G A-G - - 
TF37806 KZN >128 >128 >16 - A-G A-G - - 
TF2981 KZN >128 >128 >16 - A-G A-G - - 
MODS334 KZN >128 >128 >16 - A-G A-G - - 
TF2038 KZN >128 >128 >16 - A-G A-G - - 
TF3228 KZN >128 >128 >16 - A-G A-G - - 
TF25027 KZN >128 >128 >16 - A-G A-G - - 
TF51648 KZN >128 >128 >16 - A-G A-G - - 











Table A 4.5: MIC and sequencing data for the fluoroquinolones, PAS and linezolid 
SUSCEPTIBLE RFLP MIC 
mg/L 
gyrA gyrB PAS thyA 
 
LIN rrl 
  CIP OFX MFX 61 269 284  604 2399 
TF1538 U 0.5 0.5 0.125 G-C - G-C - - - 
TF1413 B 0.5 0.5 0.125 G-C - G-C - - - 
TF1582 B 0.5 0.5 0.125 G-C - G-C - - - 
TF832 F11V 0.5 0.5 0.125 G-C - G-C - - - 
TF1519 B 0.5 0.5 0.125 G-C - G-C - - - 
TF1001 U 0.5 0.5 0.125 G-C - G-C - - - 
TF933 U 0.5 0.5 0.125 G-C - G-C - - - 
P090811 B 0.5 0.5 0.125 G-C - G-C - - - 
P090802 B 0.5 0.5 0.125 G-C - G-C - - - 
P090804 B 0.5 0.5 0.125 G-C - G-C - - - 
H37Rv  0.5 0.5 0.125 G-C - G-C - - - 
MDR RFLP CIP OFX MFX 61 269 284  PAS thyA 
 
LIN rrl 
MODS11 KZN 1 1 0.5 G-C - G-C - A-G G-A 
MODS688 KZN 1 1 0.5 G-C - G-C - A-G G-A 
TF44949 F28 1 1 0.5 G-C - G-C - - - 
TF3251 KZN 1 1 0.5 G-C - G-C - A-G G-A 
TF78838 F28 1 1 0.5 G-C - G-C - - - 
TF2063 F28 1 1 0.5 G-C - G-C - - - 
TF3203 F28 0.5 0.5 0.5 G-C - G-C - - - 
TF1951 F28V 0.5 0.5 0.125 G-C - G-C - - - 
TF64747 KZN 1 1 0.5 G-C - G-C - A-G G-A 
MODS644 F28 1 1 0.5 G-C - G-C - - - 
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TF2889 F28 1 1 0.5 G-C - G-C - - - 
MDR RFLP MIC 
mg/L 
gyrA gyrB PAS thyA 
 
LIN rrl 
  CIP OFX MFX 61 269 284  - - 
TF2040 F28 1 1 0.25 G-C - G-C - - - 
MODS682 F28 1 1 0.25 G-C - G-C - - - 
TF36480 KZN 1 1 0.25 G-C - G-C - A-G G-A 
TF2034 U 1 1 0.25 G-C - G-C - - - 
TF2153 F28 1 1 0.25 G-C - G-C - - - 
XDR  CIP OFX MFX 61 269 284  PAS thyA 
 
LIN rrl 
TF1762 KZN 8 8 1 G-C C-T G-C - A-G G-A 
MODS141 KZN 8 8 2 G-C C-T G-C - A-G G-A 
MODS39 KZN 8 8 2 G-C C-T G-C - A-G G-A 
MODS387 KZN 8 8 2 G-C C-T G-C - A-G G-A 
MODS338 KZN 8 8 2 G-C C-T G-C - A-G G-A 
MODS667 KZN 8 8 2 G-C C-T G-C - A-G G-A 
MODS642 KZN 8 8 2 G-C C-T G-C - A-G G-A 
MODS513 KZN 8 8 2 G-C C-T G-C - A-G G-A 
MODS143 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF1824 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF1925 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF66937 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF3334 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF80198 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF80164 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF1497 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF75549 KZN 8 8 2 G-C C-T G-C - A-G G-A 
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TF31066 KZN 8 8 1 G-C C-T G-C - A-G G-A 
TF739 KZN 8 8 2 G-C C-T G-C - A-G G-A 
XDR RFLP MIC 
mg/L 
gyrA gyrB PAS thyA 
 
LIN rrl 
  CIP OFX MFX 61 269 284  A-G G-A 
MODS370 KZN 8 8 1 G-C C-T G-C - A-G G-A 
TF3181 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF37806 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF2981 KZN 8 8 2 G-C C-T G-C - A-G G-A 
MODS334 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF2038 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF3228 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF25027 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF51648 KZN 8 8 2 G-C C-T G-C - A-G G-A 
TF49127 KZN 8 8 2 G-C C-T G-C - A-G G-A 











Appendix 5: gidB sequence analysis 
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